The Contribution of Fibrinogen and Red Blood Cells to Arterial Thrombosis by Walton, Bethany
THE CONTRIBUTION OF FIBRINOGEN AND RED BLOOD CELLS TO  
ARTERIAL THROMBOSIS 
 
 
 
 
 
Bethany Lynne Walton 
 
 
 
 
 
“A dissertation submitted to the faculty at the University of North Carolina at Chapel Hill in 
partial fulfillment of the requirements for the degree of Doctor of Philosophy in the Department 
of Pathology and Laboratory Medicine in the School of Medicine.” 
 
 
 
 
 
Chapel Hill  
2015 
 
 
 
 
 
Approved by: 
 
                                                                                                                 Alisa S. Wolberg 
 
                                                                                                                      William B. Coleman 
 
                                                                                                               Brian C. Cooley 
 
                                                                                                         Nigel S. Key 
 
                                                                                                              Leslie V. Parise 
 
 
!
!
ii  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2015 
Bethany Lynne Walton 
ALL RIGHTS RESERVED
!
!
iii  
 
 
 
 
 
ABSTRACT 
 
Bethany Lynne Walton: The Contribution of Fibrinogen and Red Blood Cells to  
Arterial Thrombosis 
(Under the direction of Alisa S. Wolberg) 
 
 
Cardiovascular disease is the leading cause of death and disability worldwide.  This 
dissertation explores the role of the clotting factor fibrinogen and red blood cells (RBCs) to 
arterial thrombosis. 
Elevated plasma fibrinogen is associated with arterial thrombosis in humans and 
directly promotes thrombosis in mice, but the contribution of the γA/γ′ fibrinogen isoform to 
thrombosis is controversial.  To determine if γA/γ′ is prothrombotic, we separated γA/γA and 
γA/γ′ from human plasma and determined the effects on in vitro clot formation and on in vivo 
thrombus formation.  Both γA/γA and γA/γ′ were cleaved by murine and human thrombin 
and were incorporated into murine and human clots.  When γA/γA or γA/γ′ was spiked into 
plasma, γA/γA increased the fibrin formation rate to a greater extent than γA/γ′.  In mice, 
compared to controls, γA/γA infusion shortened the time to carotid artery occlusion, whereas 
γA/γ′ infusion did not.  Additionally, γA/γ′ infusion led to lower levels of plasma thrombin–
antithrombin complexes following arterial injury, whereas γA/γA infusion did not.  These 
data suggest that γA/γ′ binds thrombin in vivo and decreases prothrombotic activity. Together, 
these findings indicate that elevated levels of γA/γA promote arterial thrombosis in vivo, 
whereas γA/γ′ does not.   
!
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RBCs are the most abundant cell type in blood and increased hematocrit is associated 
with thrombosis.  While it is known that RBCs support thrombin generation and increase 
platelet activation and aggregation, the specific mechanism by which RBCs influence 
clotting is unclear.  In reconstituted human blood ex vivo, RBCs dose-dependently increased 
thrombin generation in the absence of platelets, although effects were blunted or absent in the 
presence of platelets.  Compared to controls, mice infused with RBCs formed thrombi at a 
faster rate and had a shortened time to vessel occlusion in a carotid artery injury model.  
Interestingly, there was no difference in circulating thrombin-antithrombin complexes 
between RBCHIGH and control mice, and thrombi did not differ in size or fibrin content, 
suggesting elevated hematocrit promotes arterial thrombosis by a thrombin-independent 
mechanism.  Our data suggest that reducing hematocrit may reduce arterial thrombosis in 
humans. Future experiments will investigate how the RBC effect on platelets contributes to 
thrombosis.   
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Chapter 1: Introduction: Fibrinogen and Red Blood Cells in Hemostasis and 
Thrombosis1 
 
 
1.1 Introduction 
 
Arterial thrombosis is a leading cause of death and disability worldwide.  Arterial 
thrombosis is usually initiated following rupture of an atherosclerotic plaque.  This causes the 
formation of thrombi that may become occlusive and cause ischemic damage to the 
surrounding tissues.  Intracardiac thrombosis may also occur due to atrial fibrillation or the 
presence of a mechanical valve [1].  Arterial thrombi are usually termed “white-thrombi” due 
to their high platelet count and efforts to understand the pathogenesis of arterial thrombosis 
have mainly focused on platelets.  However growing evidence suggests that the plasma 
protein fibrin(ogen) and RBCs may also be involved in the development of arterial thrombi. 
 Venous thrombosis is initiated by endothelial dysfunction and inappropriate 
expression of plasma and cellular procoagulant activity under low blood flow/stasis (so-
called Virchow’s Triad). The epidemiology, risk factors, and treatment of venous thrombosis 
have been recently reviewed in [2].  However, the pathophysiologic mechanisms that 
contribute to thrombus formation, composition, and stability are still poorly understood. 
Clues may be found in the distinctive appearance of venous thrombi, which demonstrate 
regions of high RBC and fibrin content (so-called “red thrombi”). Notably, RBCs can be 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
1!This chapter is based on, and reproduced in-part with permission from: Walton BL, Byrnes 
JR, Wolberg AS. Fibrinogen, red blood cells, and factor XIII in venous thrombosis. J 
Thromb Haemost. 2015, In Press 
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found between layers of fibrin in a “brick and mortar” construction, where they lose their 
typical discoid shape and acquire a compressed morphology (so-called “polyhedrocytes”) [3]. 
These observations suggest RBCs and fibrin(ogen) interact during venous thrombosis, and 
that thrombi undergo substantial consolidation during their maturation.   
  Herein, I will review the contributions of fibrinogen and RBCs to coagulation, and 
provide evidence supporting their potential roles in both arterial and venous thrombosis.   
 
1.2 Fibrinogen 
1.2.1 Fibrinogen structure, fibrin formation, and fibrin mechanical properties.
 The fibrinogen molecule consists of 2 sets each of 3 polypeptide chains (AαBβγ)2.  
During coagulation, thrombin cleaves N-terminal peptides from the Aα- and Bβ-chains 
promoting the formation of protofibrils and subsequently, fibrin fibers.  Branching results in 
the characteristic fibrin network seen in micrographs of purified and plasma clots.  
Fibrinogen circulates at high concentrations (2-4 mg/mL) in plasma, and levels may increase 
further during inflammation.  The concentrations of thrombin and fibrinogen present during 
clot formation influence fibrin network structure and stability.  For example, clots formed in 
the presence of high thrombin or fibrinogen concentrations have increased fibrin network 
density and resistance to fibrinolysis compared to clots formed under normal conditions. 
These processes have been previously reviewed [4, 5]. 
Crosslinked fibrin is also known for its ability to stabilize clots.  This property is 
determined at both micro- and macro-scales.  Individual fibrin fibers have astounding 
viscoelasticity.  Crosslinked fibrin fibers can be stretched to 2.5-times their original length 
before rupturing, making fibrin as extensible as spider silk [6-8].  Moreover, elastic recovery 
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of fibers from elongations up to 100% can occur within milliseconds [9].  Branchpoints 
within the fibrin network are surprisingly strong.  When strained, individual fibers fail before 
branchpoints fail [10].  Thus, it is not surprising that fully-formed fibrin clots have similar 
extensibility and elasticity as individual fibers.  
 
1.2.2 Fibrinogen and arterial and venous thrombosis.  
Elevated total fibrinogen is correlated with increased arterial thrombosis [11-15] and 
increased venous thrombosis risk [16-20], and risk is concentration-dependent and present in 
both men and women.  Studies using transgenic mice and murine infusion models have 
associated elevated fibrinogen with increased prothrombotic biomarkers (e.g., D-dimer) [21] 
and a shorter time to vessel occlusion and increased thrombus fibrin content [22].  Moreover, 
compared to control mice, thrombi in fibrinogen-infused mice also show increased resistance 
to fibrinolysis [22].  These findings suggest hyperfibrinogenemia is not merely a biomarker 
of thrombosis risk, but is causative in arterial and venous thrombosis etiology.  
 
1.2.3 Abnormal fibrin structure and stability in thrombosis.  
Several studies have reported abnormal fibrin structure and/or stability in both arterial 
and venous thrombosis, even when circulating fibrinogen levels are normal.  For example, 
compared to controls, patients with a history of MI produced clots with shorter fibrin fibers 
with increased stiffness, and an increased resistance to lysis [23, 24].  Additionally, 
compared to controls, plasma clots from patients with acute ischemic and cryptogenic stroke 
also displayed reduced permeability and resistance to lysis [25, 26].  In venous thrombosis, 
plasma clots from patients with a history of idiopathic venous thrombosis show increased 
! 4 
fibrin network density, reduced permeability, and increased lysis times[27].  Interestingly, 
compared to plasma clots from patients with deep vein thrombosis, clots from patients that 
experienced pulmonary embolism are less compact and more susceptible to fibrinolysis [27, 
28].   In total, these data suggest abnormal fibrin network structure and stability contribute to 
arterial and venous thrombosis. 
 
1.2.4 Fibrinogen γ’-chain and arterial and venous thrombosis.  
The fibrinogen γ-chain can undergo alternative splicing, leading to replacement of 4 
C-terminal amino acids with a unique 20 amino acid sequence (γ’; Figure 1.1).  The γ’-chain 
is present in 8-15% of fibrinogen molecules (as γA/γ’) in healthy individuals.  The genes 
encoding the fibrinogen chains are co-regulated to maintain the level of fibrinogen in 
circulation (reviewed in [29]).  However, the levels of the γA- and γ’-chains are mediated by 
independent mechanisms that differentially regulate their expression.  Expression of γ’-
containing fibrinogen is disproportionally increased by interleukin-6-dependent 
inflammatory responses [30], suggesting an independent relationship between the γ’-chain, 
inflammation, and thrombosis.  Accordingly, although total fibrinogen levels are positively 
correlated with thrombosis risk, the fraction of circulating γ’-fibrinogen (γ’/total fibrinogen 
ratio) modulates risk independently of the total fibrinogen level.  Notably, an elevated γ’-to-
total fibrinogen ratio is associated with increased risk of arterial thrombosis in numerous 
epidemiological studies [31-36], suggesting γ’ may be driving arterial thrombosis.  
Interestingly, a reduced γ’-to-total fibrinogen ratio is associated with increased risk of venous 
thrombosis, suggesting γ’ fibrinogen is protective in venous thrombosis [37, 38].  These 
studies suggest the fibrinogen γ’-chain plays different roles in different vascular beds.  
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Determining the operant mechanisms has been difficult because γA/γ’ fibrinogen has 
both procoagulant and antithrombotic properties (reviewed in [39]).  Briefly, compared to 
γA/γA clots, clots that contain γ’ fibrinogen have a denser network of thin fibrin fibers, 
reduced permeability, reduced plasminogen binding, and increased resistance to fibrinolysis. 
The γ’-chain can also bind and sequester thrombin, protecting it from inactivation by 
antithrombin.  These properties are consistent with prothrombotic functions.  However, γ’ 
fibrinogen also exhibits impaired polymerization.  Recent studies have shown that a γ’ 
carboxyl-terminal peptide reduces plasma thrombin generation even in the presence of anti-
factor VIII antibody, suggesting γ’/thrombin interactions reduce factor V activation [40].  By 
reducing thrombin generation, this peptide also increases the sensitivity of coagulation to 
activated protein C, thus augmenting endogenous anticoagulant mechanisms [41].  
 Studies to determine the contribution of the γ’-chain to thrombosis in vivo have 
consistently demonstrated antithrombotic effects.  Transgenic expression of the human γ’-
chain reduces venous thrombus volume in mice that are heterozygous for the factor V Leiden 
mutation [42].  A peptide mimicking the γ’-chain C-terminus inhibits fibrin-rich thrombus 
formation in a baboon model of thrombosis [43].  We recently infused mice with identical 
levels of either γA/γA or γA/γ’ fibrinogen isolated from human plasma [44].  Compared to 
controls, γA/γA infusion shortens the time to carotid artery occlusion, whereas γA/γ’ infusion 
does not.  Additionally, γA/γ’ infusion reduces levels of circulating thrombin-antithrombin 
complexes.  These data are consistent with the premise that the γ’-chain reduces thrombin 
activity.  By extension, these data implicate the γA-chain as the prothrombotic mediator in 
hyperfibrinogenemia-related thrombosis.  These experiments are discussed in detail in 
! 6 
Chapter 2 of this dissertation. Together, these findings illustrate pleotropic contributions of 
fibrinogen to arterial and venous thrombosis.   
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Figure 1.1: The fibrinogen γ chain undergoes alternative processing to form the γA and 
γ’ isoforms.  The fibrinogen γ-chain mRNA transcript may undergo splicing at two main 
polyadenylation sites.  The γA-chain forms when polyadenylation (pA) occurs downstream 
of exon 10 (pA2), leading to translation of exon 10 and the formation of a γ-chain with 10 
exons, 9 introns, and 411 amino acids (ending in AGDV).  The γ’-chain forms when 
polyadenylation occurs upstream of exon 10 (pA1), forming a γ-chain which includes intron 
9.  This results in the translation of an extra 20 amino from intron 9 
(VRPEHPAETRYDSLYPEDDL), forming a γ-chain with 427 amino acids.  
EXON%9% EXON%10%INTRON%9%
pA2$
EXON%9% EXON%10%
AGDV$
pA1$
Fibrinogen$Gamma$Chain$Gene$
γA$Fibrinogen$
pA2$
VRPEHPAETEYDSLYPEDDL$
EXON%9% INTRON%9%
pA1$
γ’$Fibrinogen$
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1.2.5 Fibrin(ogen) interactions with cells and blood proteins.  
 Most studies of fibrin(ogen) function have used purified systems or plasmas. These 
studies have identified binding sites on fibrin(ogen) for soluble proteins involved in clot 
formation, stabilization, and fibrinolysis, including thrombin, FXIII, fibronectin, tissue-type 
plasminogen activator (tPA), plasminogen, and plasmin [45-49].  Notably, however, 
fibrin(ogen) also interacts with cells and these interactions may contribute to the 
incorporation of cells into venous thrombi. For example, fibrin(ogen) contains recognition 
sequences for integrins including αMβ2, αIIbβ3, αVβ3, which mediate fibrin(ogen) 
interactions with leukocytes, platelets, and endothelial cells, respectively [50]. These 
interactions modulate leukocyte function, platelet aggregation and clot retraction, and may 
anchor thrombi to the endothelium.  Fibrin(ogen) also binds to RBCs, which influences both 
the erythrocyte sedimentation rate and blood viscosity (discussed below) [51-53]. 
 
1.3 Red Blood Cells 
1.3.1 RBCs in circulation.  
RBCs are anucleate cells derived from bone marrow and are the largest cellular 
component of blood.  RBCs have a characteristic biconcave and flexible shape that allows 
them to traverse the microvasculature and fulfill their primary function of hemoglobin-
mediated oxygen transport throughout the body.  RBCs circulate at ~4.2-6.1x109/mL, 
although levels are slightly higher in men than women.  Clinical observations suggest RBC 
levels contribute to hemostasis and thrombosis.  Bleeding times shorten as hematocrit rises 
[54-57], and elevated levels of RBCs are associated with increased risk of thrombosis [58-61]. 
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1.3.2 Causes of high hematocrit.  
The normal range of RBCs in blood (hematocrit) is 41-46% in men and 36-44% in 
women, and can be influenced by a number of physiologic and pathologic situations.  In high 
altitude, the bone marrow increases RBC production to compensate for decreased oxygen 
saturation [62].  RBC levels may also increase in disease states such as polycythemia vera 
(PV) [63] and as a result of increased erythropoietin, either through exogenous erythropoietin 
use or abnormal erythropoietin production by certain types of tumors [64].  Conditions 
associated with hypoxia, such as smoking, lung disease, and heart disease, are also associated 
with increased RBC production [64]. 
 
1.3.3 Hematocrit in arterial and venous thrombosis.   
Thrombosis is a common complication in patients with PV, with arterial thrombosis 
including MI and cerebrovascular events making up the majority of all thrombotic events in 
these patients [65].  The Cytoreductive Therapy in Polycythemia Vera (CYTO-PV), a large-
scale, multicenter, prospective, randomized clinical trial compared maintaining hematocrit 
<45% or between 45-50% in patients with PV [66].  Compared to maintaining a hematocrit 
<45%, maintaining hematocrit in the higher range was associated with four times the rate of 
death from CVD and major thrombosis suggesting hematocrit is a cause for thrombosis in PV.  
However, this study did not control for patients taking hydroxyurea which complicates the 
interpretation of these results. 
Numerous longitudinal, prospective studies have suggested elevated hematocrit is 
associated with both arterial and venous thrombosis in patients with an elevated hematocrit 
not caused by PV.  However these studies are more conflicted in their results.  Some studies 
! 10 
suggest hematocrit is not independently associated with thrombosis [67, 68] while other 
studies find an association [15, 58, 60, 69].  Similar conflicted findings are seen in studies on 
elevated hematocrit and venous thrombosis [70-72]. These studies are summarized in Tables 
1.1 and 1.2.  Thus it is hard to reconcile the role of elevated hematocrit in thrombosis.  
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Table 1.1 Epidemiological studies are conflicted on the association between hematocrit 
and arterial thrombosis 
Study N Methods Results 
Sorlie (1981) 
Puerto Rico 
Health 
Program [58] 
-2555 
Rural/6151 urban 
men (45-64 years 
old) 
 
-Subjects examined 3 
times in 8 year follow-
up 
-High HCT (>49%) 
associated with an increased 
risk of MI, coronary 
insufficiency, and CHD 
death compared to low HCT 
(<42%).   
-Risk more than double in 
high HCT group 
Carter (1983) 
[68] 
-8006 Japanese 
men 
 
-Subjects completed 
questionnaires & 
underwent interviews & 
medical screening 
-10 year follow-up   
-HCT correlated with 
predictors or CHD risk, 
related to non-fatal MI, CHD 
death, and total CHD 
-When adjusted for other 
variables, HCT not 
independent risk factor 
Gagnon 
(1994) 
Framingham 
Study [60] 
-5209 men & 
women (30-62 
years old) 
-1073 deaths 
 
-Subjects received 
biannual examinations 
-34 year follow-up 
-Men and women in the 
highest HCT quintile had 
increased risk of CVD death 
(men ≥49%; women ≥46%) 
-Correlation strongest in 
younger men 
Brown (2001) 
Second 
National 
Health & 
Nutrition 
Examination 
Survey 
(NHANES II) 
Mortality 
Study [67] 
-8896 men & 
women (30-75 
years old) 
-HCT categorized by 
sex-specific tertiles 
-16.8 year follow-up 
-Women in the upper tertile 
were 1.3 times more likely 
to die from CHD than 
women with HCT in lowest 
tertile after multivariate 
adjustment  
-Risk was stronger in 
women <65 years old  
-HCT not associated with 
CVD or death in men after 
multivariate adjustment 
Kunnas 
(2009) 
TAMRISK 
Study [69] 
-670 Finnish 
Men (55 years 
old) 
-188 deaths from 
CVD 
 
-Health survey data 
taken on 670 men in 
1980  
-28 year follow-up  
-Divided into two 
groups-HCT ≥50 or <50 
-Men with HCT >50% were 
2.4 more likes to die from 
CHD than men with HCT 
<50%  
-After adjusting for CHD 
risk factors, risk was 1.8 fold  
Toss (2013)  
[61] 
-417,099 
Swedish men 
(18-19 years old) 
-9322 1st MI 
-Baseline health tests 
and measures during 
conscription 
-36 year follow-up 
 
-HCT ≥49% had a 1.4 fold 
increased risk of MI 
compared to men with HCT 
≤44%.  
-Dose dependent 
relationship and remained 
constant through follow-up 
period. 
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Table 1.2 Epidemiological studies are conflicted on the association between hematocrit 
and venous thrombosis 
 
 
  
Study N Methods Results 
Tsai (2002) 
The Longitudinal 
Investigation of 
Thromboembolism 
Etiology [70] 
 
19292 
men & 
women 
-Combines data from, 
the Atherosclerosis 
Risk In Communities 
(ARIC) study and 
Cardiovascular Heath 
Study (CHS) 
-8 year follow-up 
-No relation between 
HCT and VTE 
-Limitation: Low 
HCT cut-off at 43.5%  
 
Vaya (2002) [71] -109 1st 
time 
VTE 
patients 
-121 
controls 
 -Subjects had no 
inherited or acquired 
risk factors for DVT 
-DVT documented 
with ultrasonography 
or venography and 
PE with ventilation 
perfusion scanning or 
pulmonary 
angiography 
-Blood collected from 
patients 6-36 months 
after the VTE episode 
(85% collected within 
the first year) 
-No relation between 
HCT, RBC 
aggregation, plasma 
viscosity and DVT 
Braekkan (2010) 
Tromsø Study [72] 
-26108 
men & 
women 
 
- 12.5 year follow-up -Multivariate hazard 
ratios per 5% increase 
in HCT were 1.25 for 
total VTE and 1.37 for 
unprovoked VTE.  
-Men with HCT in 
upper 20th percentile 
had a 1.5-fold 
increased risk for total 
VTE and 2.4-fold risk 
for unprovoked VTE 
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1.3.4 RBCs mediate blood rheology.   
Hemorheology is the study of how flowing blood influences hemostasis.  RBCs are 
the major determinant of blood rheology because of their prevalence, size, deformability, and 
ability to undergo reversible aggregation.  Under high shear in the arterial circulation, 
(typically 500-1500 s-1), RBCs promote platelet flux toward the vessel wall (so-called 
platelet margination), which increases the frequency of platelet-endothelial cell interactions, 
and platelet-platelet interactions which promotes platelet adhesion, activation, and 
aggregation (Figure 1.2) [73].  However, under low shear in the venous circulation (typically 
10-100 s-1), RBCs increase blood viscosity via their tendency to aggregate (rouleaux 
formation).  Increased blood viscosity is a risk factor for arterial and venous thrombosis [74-
76].  Notably, RBC aggregation is mediated by plasma proteins including fibrinogen [51-53].  
Consequently, inflammatory processes that increase fibrinogen levels also increase blood 
viscosity.  These effects have been implicated in the association between elevated hematocrit 
and hyperfibrinogenemia with thrombosis.  However, it remains unclear whether this 
relationship is correlative or causative.  
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Figure 1.2: RBCs marginate platelets toward the vessel wall under arterial shear. RBCs 
dominate the rheology of blood due to their high number, large size, and deformability.  
Under the high shear rates present in arteries, RBCs move toward the center of the blood 
vessel.  This marginates platelets towards the arterial walls, which promotes increased 
platelet-platelet interactions and platelet-endothelial interactions.  
RBC$
Platelets$
Blood$Flow$
Smooth$Muscle$Cell$
Endothelial$Cell$
Collagen$
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1.3.5 RBCs interact with fibrin(ogen).  
RBCs interact specifically with fibrin(ogen) and the fibrinogen motif that mediates 
RBC interactions involve fibrinogen Aα-chain residues 207-303 [51].  Two potential RBC 
receptors have been implicated in this interaction.  Fibrinogen-RBC interactions can be 
inhibited by the integrin-blocking molecule eptifibatide and are not supported by RBCs 
lacking β3 isolated from patients with Glanzmann thrombasthenia [77], implicating β3 or a 
β3-like molecule on the RBC surface. However, that study did not rule out the possibility that 
RBC-bound platelets mediate this interaction [77].  Fibrinogen-RBC interactions can also be 
blocked with an antibody against the integrin-associated protein CD47 [78]. Since CD47 was 
originally identified for its interaction with αvβ3, αIIbβ3, and α2β1 integrins, it is possible 
that the RBC binding site comprises a complex with both of these molecules.   It is 
interesting to speculate that that blocked fibrin(ogen)-RBC interactions may reduce whole 
blood viscosity and thus thrombosis risk. 
 
1.3.6 RBCs interact with cells.   
RBCs can interact with leukocytes, platelets, and endothelial cells.  For example, 
RBC ICAM-4 can bind leukocyte β1 and β2 integrins [79, 80] and platelet αIIbβ3 [81].  RBC 
ICAM-4 also interacts with integrin αv [82].  RBCs are the first cells to adhere to ferric 
chloride (FeCl3)-treated, intact arterial endothelium, prior to the arrival of platelets [83].  This 
interaction is not dependent on von Willebrand factor or GPIbα.  However, the molecular 
receptors on RBCs and the endothelium that mediate this interaction have not been identified 
[83].  Interestingly, RBCs exhibit temporal changes in gene expression during erythropoiesis 
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[84], suggesting stage-specific receptors may decorate RBCs during differentiation and 
further refine these interactions.  
 
1.3.7 RBCs influence platelet reactivity.   
RBCs have been shown to alter the biochemical responsiveness and functional 
responsiveness of activated platelets [85].  Silvain et al. [86] showed that RBCs increase 
ADP-induced platelet activation and aggregation in vitro in blood from healthy volunteers.  
The same group went on to show that patients who received RBC transfusions displayed 
increased ADP-induced platelet reactivity [87].  Moreover, it was specifically shown that 
RBCs amplify platelet activation and degranulation by increasing platelet serotonin release, 
increasing enzymatic ADP removal, and inhibiting proteases [85].  The increase in platelet 
reactivity by RBCs could not be decreased by aspirin, suggesting that RBC level influences 
therapeutic effect of aspirin.  RBCs have also been shown to enhance the activation of αIIbβ3 
and P-selectin on platelets, suggesting RBCs increase platelet activation and aggregation [88].  
In sum, these studies suggest that RBCs contribute to thrombus formation by increasing 
platelet reactivity. 
 
1.3.8 RBCs support thrombin generation.  
A small percentage (~0.5%) of RBCs circulate with exposed phosphotidylserine (PS) 
on their outer membranes [89], suggesting RBCs can assemble prothrombinase complexes 
and support thrombin generation (Figure 1.3).  Interestingly, although levels of both PS-
positive RBCs and platelets are elevated in patients with sickle cell disease (SCD) genotypes, 
only PS-positive RBCs correlate with circulating biomarkers of coagulation activation, 
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including F1.2 and D-dimer [89].  This finding suggests PS-positive RBCs are the primary 
cell responsible for thrombophilia in SCD.  In vitro studies support this premise; when added 
to platelet-poor plasma, RBCs shorten the lag time and increase the peak of thrombin 
generation similar to that seen with platelets [90, 91], although in contrast to platelets, 
thrombin generation on RBCs occurs through the meizothrombin pathway [92].  RBCs can 
also produce microvesicles that activate procoagulant and complement pathways in vitro [93-
95]. 
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Figure 1.3: A portion of RBCs express PS on their cell membrane.  A small percentage 
(0.5%) of RBCs express PS exposure on their cell surface.  This surface allows for 
prothrombinase complex assembly, prothrombin conversion to thrombin, and fibrin 
formation.  Fibrin can then be crosslinked by the transglutaminase factor XIII, to form the 
structural support for a clot.   
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1.3.9 RBCs alter fibrin structure and stability.  
RBCs alter fibrin network structure [96, 97] and reduce fibrin network permeability 
[98]. RBCs also suppress plasmin generation and reduce clot dissolution [97].  In the 
presence of the substantial contractile forces induced by platelets during clot retraction [99, 
100], RBCs are dramatically compressed, which further reduces clot permeability and 
restricts access of fibrinolytic enzymes to the clot [3, 101].  Importantly, this phenomenon 
was noted in thrombi harvested from the arterial vasculature [3] but is also likely to have a 
significant impact on venous thrombosis, since these thrombi contain platelets and large 
numbers of RBCs.  These data suggest reducing RBC content in thrombi may increase clot 
dissolution, thus reducing thrombosis. 
 
1.4 Conclusions 
Both fibrinogen and RBCs are essential components of blood and major players in 
coagulation.  Continued studies are needed to delineate the pathophysiologic mechanisms 
that mediate the roles of both fibrinogen and RBCs in thrombosis.  Specifically, identifying 
the specific fibrinogen isoform that promotes thrombosis and knowledge of the role of 
elevated hematocrit in thrombosis will provide new insight into mechanisms that drive 
abnormal clot formation.  Additionally, identification of the RBC-receptor that binds 
fibrinogen may provide new therapeutic targets to prevent thrombosis. 
 
1.5 Focus of this dissertation 
Growing evidence suggests fibrinogen and RBCs play an important role in arterial 
thrombosis.  Previous work on the role of fibrinogen in arterial thrombosis has focused on 
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total fibrinogen (combined γA/γA and γA/γ’) and previous work on RBCs in arterial 
thrombosis has been performed in murine models with co-morbidities.  Therefore, this 
dissertation will specifically focus on i) the effect of the γA/γA and γA/γ’ individually to 
arterial thrombosis, and ii) the influence of elevated hematocrit to arterial thrombosis in a 
RBCs transfusion model of elevated hematocrit.  Knowledge on how fibrinogen isoforms and 
RBCs contribute to thrombosis may help elucidate mechanisms involved in the formation of 
arterial thrombi, reveal biomarkers to predict thrombosis, and provide clues into the best 
strategies to prevent thrombosis. 
  
! 21 
 
  REFERENCES 
 
1 Previtali E, Bucciarelli P, Passamonti SM, Martinelli I. Risk factors for venous and 
arterial thrombosis. Blood Transfus. 2011; 9: 120-38. 
2 Wolberg AS, Rosendaal FR, Weitz JI, Jaffer IH, Agnelli G, Baglin T, Mackman N. 
Venous Thrombosis. Nat Rev Dis Pri, In Press. 2015. 
3 Cines DB, Lebedeva T, Nagaswami C, Hayes V, Massefski W, Litvinov RI, Rauova 
L, Lowery TJ, Weisel JW. Clot contraction: compression of erythrocytes into tightly 
packed polyhedra and redistribution of platelets and fibrin. Blood. 2013. 
4 Lord ST. Molecular mechanisms affecting fibrin structure and stability. Arterioscler 
Thromb Vasc Biol. 2011; 31: 494-9. 
5 Wolberg AS. Thrombin generation and fibrin clot structure. Blood Rev. 2007; 21: 
131-42. 
6 Collet JP, Shuman H, Ledger RE, Lee S, Weisel JW. The elasticity of an individual 
fibrin fiber in a clot. Proc Natl Acad Sci U S A. 2005; 102: 9133-7. 
7 Liu W, Carlisle CR, Sparks EA, Guthold M. The mechanical properties of single 
fibrin fibers. J Thromb Haemost. 2010; 8: 1030-6. 
8 Liu W, Jawerth LM, Sparks EA, Falvo MR, Hantgan RR, Superfine R, Lord ST, 
Guthold M. Fibrin fibers have extraordinary extensibility and elasticity. Science. 
2006; 313: 634. 
9 Hudson NE, Ding F, Bucay I, O'Brien ET, 3rd, Gorkun OV, Superfine R, Lord ST, 
Dokholyan NV, Falvo MR. Submillisecond elastic recoil reveals molecular origins of 
fibrin fiber mechanics. Biophys J. 2013; 104: 2671-80. 
10 Carlisle CR, Sparks EA, Der Loughian C, Guthold M. Strength and failure of fibrin 
fiber branchpoints. J Thromb Haemost. 2010; 8: 1135-8. 
! 22 
11 Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L. Markers of myocardial 
damage and inflammation in relation to long-term mortality in unstable coronary 
artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery 
Disease. N Engl J Med. 2000; 343: 1139-47. 
12 Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. 
Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med. 1984; 
311: 501-5. 
13 Acevedo M, Pearce GL, Kottke-Marchant K, Sprecher DL. Elevated fibrinogen and 
homocysteine levels enhance the risk of mortality in patients from a high-risk 
preventive cardiology clinic. Arterioscler Thromb Vasc Biol. 2002; 22: 1042-5. 
14 Kannel WB, Wolf PA, Castelli WP, D'Agostino RB. Fibrinogen and risk of 
cardiovascular disease. The Framingham Study. JAMA. 1987; 258: 1183-6. 
15 Toss H, Lindahl B, Siegbahn A, Wallentin L. Prognostic influence of increased 
fibrinogen and C-reactive protein levels in unstable coronary artery disease. FRISC 
Study Group. Fragmin during Instability in Coronary Artery Disease. Circulation. 
1997; 96: 4204-10. 
16 Koster T, Rosendaal FR, Reitsma PH, van der Velden PA, Briet E, Vandenbroucke JP. 
Factor VII and fibrinogen levels as risk factors for venous thrombosis. A case-control 
study of plasma levels and DNA polymorphisms--the Leiden Thrombophilia Study 
(LETS). Thromb Haemost. 1994; 71: 719-22. 
17 Haverkate F, Samama M. Familial dysfibrinogenemia and thrombophilia. Report on a 
study of the SSC Subcommittee on Fibrinogen. Thromb Haemost. 1995; 73: 151-61. 
18 Austin H, Hooper WC, Lally C, Dilley A, Ellingsen D, Wideman C, Wenger NK, 
Rawlins P, Silva V, Evatt B. Venous thrombosis in relation to fibrinogen and factor 
VII genes among African-Americans. J Clin Epidemiol. 2000; 53: 997-1001. 
19 Kamphuisen PW, Eikenboom JC, Vos HL, Pablo R, Sturk A, Bertina RM, Rosendaal 
FR. Increased levels of factor VIII and fibrinogen in patients with venous thrombosis 
are not caused by acute phase reactions. Thromb Haemost. 1999; 81: 680-3. 
20 van Hylckama Vlieg A, Rosendaal FR. High levels of fibrinogen are associated with 
the risk of deep venous thrombosis mainly in the elderly. J Thromb Haemost. 2003; 1: 
2677-8. 
! 23 
21 Kerlin B, Cooley BC, Isermann BH, Hernandez I, Sood R, Zogg M, Hendrickson SB, 
Mosesson MW, Lord S, Weiler H. Cause-effect relation between 
hyperfibrinogenemia and vascular disease. Blood. 2004; 103: 1728-34. 
22 Machlus KR, Cardenas JC, Church FC, Wolberg AS. Causal relationship between 
hyperfibrinogenemia, thrombosis, and resistance to thrombolysis in mice. Blood. 
2011; 117: 4953-63. 
23 Collet JP, Allali Y, Lesty C, Tanguy ML, Silvain J, Ankri A, Blanchet B, Dumaine R, 
Gianetti J, Payot L, Weisel JW, Montalescot G. Altered fibrin architecture is 
associated with hypofibrinolysis and premature coronary atherothrombosis. 
Arterioscler Thromb Vasc Biol. 2006; 26: 2567-73. 
24 Undas A, Zalewski J, Krochin M, Siudak Z, Sadowski M, Pregowski J, Dudek D, 
Janion M, Witkowski A, Zmudka K. Altered plasma fibrin clot properties are 
associated with in-stent thrombosis. Arterioscler Thromb Vasc Biol. 2010; 30: 276-82. 
25 Undas A, Slowik A, Wolkow P, Szczudlik A, Tracz W. Fibrin clot properties in acute 
ischemic stroke: relation to neurological deficit. Thromb Res. 2010; 125: 357-61. 
26 Undas A, Podolec P, Zawilska K, Pieculewicz M, Jedlinski I, Stepien E, Konarska-
Kuszewska E, Weglarz P, Duszynska M, Hanschke E, Przewlocki T, Tracz W. 
Altered fibrin clot structure/function in patients with cryptogenic ischemic stroke. 
Stroke. 2009; 40: 1499-501. 
27 Undas A, Zawilska K, Ciesla-Dul M, Lehmann-Kopydlowska A, Skubiszak A, 
Ciepluch K, Tracz W. Altered fibrin clot structure/function in patients with idiopathic 
venous thromboembolism and in their relatives. Blood. 2009; 114: 4272-8. 
28 Martinez MR, Cuker A, Mills AM, Crichlow A, Lightfoot RT, Chernysh IN, 
Nagaswami C, Weisel JW, Ischiropoulos H. Enhanced lysis and accelerated 
establishment of viscoelastic properties of fibrin clots are associated with pulmonary 
embolism. Am J Physiol Lung Cell Mol Physiol. 2014; 306: L397-404. 
29 Fish RJ, Neerman-Arbez M. Fibrinogen gene regulation. Thromb Haemost. 2012; 
108: 419-26. 
30 Rein-Smith CM, Anderson NW, Farrell DH. Differential regulation of fibrinogen 
gamma chain splice isoforms by interleukin-6. Thromb Res. 2013; 131: 89-93. 
! 24 
31 Lovely RS, Falls LA, Al-Mondhiry HA, Chambers CE, Sexton GJ, Ni H, Farrell DH. 
Association of gammaA/gamma' fibrinogen levels and coronary artery disease. 
Thromb Haemost. 2002; 88: 26-31. 
32 Mannila MN, Lovely RS, Kazmierczak SC, Eriksson P, Samnegard A, Farrell DH, 
Hamsten A, Silveira A. Elevated plasma fibrinogen gamma' concentration is 
associated with myocardial infarction: effects of variation in fibrinogen genes and 
environmental factors. J Thromb Haemost. 2007; 5: 766-73. 
33 Cheung EY, Vos HL, Kruip MJ, den Hertog HM, Jukema JW, de Maat MP. Elevated 
fibrinogen gamma' ratio is associated with cardiovascular diseases and acute phase 
reaction but not with clinical outcome. Blood. 2009; 114: 4603-4. 
34 Cheung EY, Uitte de Willige S, Vos HL, Leebeek FW, Dippel DW, Bertina RM, de 
Maat MP. Fibrinogen gamma' in ischemic stroke: a case-control study. Stroke. 2008; 
39: 1033-5. 
35 van den Herik EG, Cheung EY, de Lau LM, den Hertog HM, Leebeek FW, Dippel 
DW, Koudstaal PJ, de Maat MP. gamma'/total fibrinogen ratio is associated with 
short-term outcome in ischaemic stroke. Thromb Haemost. 2011; 105: 430-4. 
36 Drouet L, Paolucci F, Pasqualini N, Laprade M, Ripoll L, Mazoyer E, Bal dit Sollier 
C, Vanhove N. Plasma gamma'/gamma fibrinogen ratio, a marker of arterial 
thrombotic activity: a new potential cardiovascular risk factor? Blood Coagul 
Fibrinolysis. 1999; 10 Suppl 1: S35-9. 
37 Uitte de Willige S, de Visser MC, Houwing-Duistermaat JJ, Rosendaal FR, Vos HL, 
Bertina RM. Genetic variation in the fibrinogen gamma gene increases the risk for 
deep venous thrombosis by reducing plasma fibrinogen gamma' levels. Blood. 2005; 
106: 4176-83. 
38 Nowak-Gottl U, Weiler H, Hernandez I, Thedieck S, Seehafer T, Schulte T, Stoll M. 
Fibrinogen alpha and gamma genes and factor VLeiden in children with 
thromboembolism: results from 2 family-based association studies. Blood. 2009; 114: 
1947-53. 
39 Uitte de Willige S, Standeven KF, Philippou H, Ariens RA. The pleiotropic role of 
the fibrinogen gamma' chain in hemostasis. Blood. 2009; 114: 3994-4001. 
! 25 
40 Omarova F, Uitte De Willige S, Ariens RA, Rosing J, Bertina RM, Castoldi E. 
Inhibition of thrombin-mediated factor V activation contributes to the anticoagulant 
activity of fibrinogen gamma'. J Thromb Haemost. 2013; 11: 1669-78. 
41 Omarova F, Uitte de Willige S, Simioni P, Ariens RA, Bertina RM, Rosing J, 
Castoldi E. Fibrinogen gamma' increases the sensitivity to activated protein C in 
normal and factor V Leiden plasma. Blood. 2014; 124: 1531-8. 
42 Mosesson MW, Cooley BC, Hernandez I, Diorio JP, Weiler H. Thrombosis risk 
modification in transgenic mice containing the human fibrinogen thrombin-binding 
gamma' chain sequence. J Thromb Haemost. 2009; 7: 102-10. 
43 Lovely RS, Boshkov LK, Marzec UM, Hanson SR, Farrell DH. Fibrinogen gamma' 
chain carboxy terminal peptide selectively inhibits the intrinsic coagulation pathway. 
Br J Haematol. 2007; 139: 494-503. 
44 Walton BL, Getz TM, Bergmeier W, Lin FC, Uitte de Willige S, Wolberg AS. The 
fibrinogen γA/γ’ isoform does not promote acute arterial thrombosis in mice. J 
Thromb Haemost. 2014; 12: 680-9. 
45 Makogonenko E, Tsurupa G, Ingham K, Medved L. Interaction of fibrin(ogen) with 
fibronectin: further characterization and localization of the fibronectin-binding site. 
Biochemistry. 2002; 41: 7907-13. 
46 Meh DA, Siebenlist KR, Brennan SO, Holyst T, Mosesson MW. The amino acid 
sequence in fibrin responsible for high affinity thrombin binding. Thromb Haemost. 
2001; 85: 470-4. 
47 Siebenlist KR, Meh DA, Mosesson MW. Plasma factor XIII binds specifically to 
fibrinogen molecules containing gamma chains. Biochemistry. 1996; 35: 10448-53. 
48 Lucas MA, Fretto LJ, McKee PA. The binding of human plasminogen to fibrin and 
fibrinogen. J Biol Chem. 1983; 258: 4249-56. 
49 Thelwell C, Longstaff C. The regulation by fibrinogen and fibrin of tissue 
plasminogen activator kinetics and inhibition by plasminogen activator inhibitor 1. J 
Thromb Haemost. 2007; 5: 804-11. 
! 26 
50 Jerome WG, Handt S, Hantgan RR. Endothelial cells organize fibrin clots into 
structures that are more resistant to lysis. Microsc Microanal. 2005; 11: 268-77. 
51 Maeda N, Seike M, Kume S, Takaku T, Shiga T. Fibrinogen-induced erythrocyte 
aggregation: erythrocyte-binding site in the fibrinogen molecule. Biochim Biophys 
Acta. 1987; 904: 81-91. 
52 Lominadze D, Dean WL. Involvement of fibrinogen specific binding in erythrocyte 
aggregation. FEBS Lett. 2002; 517: 41-4. 
53 Rampling MW. The binding of fibrinogen and fibrinogen degradation products to the 
erythrocyte membrane and its relationship to haemorheology. Acta Biol Med Ger. 
1981; 40: 373-8. 
54 Small M, Lowe GD, Cameron E, Forbes CD. Contribution of the haematocrit to the 
bleeding time. Haemostasis. 1983; 13: 379-84. 
55 Valeri CR, Cassidy G, Pivacek LE, Ragno G, Lieberthal W, Crowley JP, Khuri SF, 
Loscalzo J. Anemia-induced increase in the bleeding time: implications for treatment 
of nonsurgical blood loss. Transfusion. 2001; 41: 977-83. 
56 Blajchman MA, Bordin JO, Bardossy L, Heddle NM. The contribution of the 
haematocrit to thrombocytopenic bleeding in experimental animals. Br J Haematol. 
1994; 86: 347-50. 
57 Ho CH. The hemostatic effect of packed red cell transfusion in patients with anemia. 
Transfusion. 1998; 38: 1011-4. 
58 Sorlie PD, Garcia-Palmieri MR, Costas R, Jr., Havlik RJ. Hematocrit and risk of 
coronary heart disease: the Puerto Rico Health Program. Am Heart J. 1981; 101: 456-
61. 
59 Erikssen G, Thaulow E, Sandvik L, Stormorken H, Erikssen J. Haematocrit: a 
predictor of cardiovascular mortality? J Intern Med. 1993; 234: 493-9. 
60 Gagnon DR, Zhang TJ, Brand FN, Kannel WB. Hematocrit and the risk of 
cardiovascular disease--the Framingham study: a 34-year follow-up. Am Heart J. 
1994; 127: 674-82. 
! 27 
61 Toss F, Nordstrom A, Nordstrom P. Association between hematocrit in late 
adolescence and subsequent myocardial infarction in Swedish men. Int J Cardiol. 
2013; 168: 3588-93. 
62 Tannheimer M, Fusch C, Boning D, Thomas A, Engelhardt M, Schmidt R. Changes 
of hematocrit and hemoglobin concentration in the cold Himalayan environment in 
dependence on total body fluid. Sleep Breath. 2010; 14: 193-9. 
63 Tefferi A. Polycythemia vera and essential thrombocythemia: 2013 update on 
diagnosis, risk-stratification, and management. Am J Hematol. 2013; 88: 507-16. 
64 McMullin MF. The classification and diagnosis of erythrocytosis. Int J Lab Hematol. 
2008; 30: 447-59. 
65 Landolfi R, Di Gennaro L, Falanga A. Thrombosis in myeloproliferative disorders: 
pathogenetic facts and speculation. Leukemia. 2008; 22: 2020-8. 
66 Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D, De Stefano 
V, Elli E, Iurlo A, Latagliata R, Lunghi F, Lunghi M, Marfisi RM, Musto P, Masciulli 
A, Musolino C, Cascavilla N, Quarta G, Randi ML, Rapezzi D, Ruggeri M, Rumi E, 
Scortechini AR, Santini S, Scarano M, Siragusa S, Spadea A, Tieghi A, Angelucci E, 
Visani G, Vannucchi AM, Barbui T, Group C-PC. Cardiovascular events and 
intensity of treatment in polycythemia vera. N Engl J Med. 2013; 368: 22-33. 
67 Brown DW, Giles WH, Croft JB. Hematocrit and the risk of coronary heart disease 
mortality. Am Heart J. 2001; 142: 657-63. 
68 Carter C, McGee D, Reed D, Yano K, Stemmermann G. Hematocrit and the risk of 
coronary heart disease: the Honolulu Heart Program. Am Heart J. 1983; 105: 674-9. 
69 Kunnas T, Solakivi T, Huuskonen K, Kalela A, Renko J, Nikkari ST. Hematocrit and 
the risk of coronary heart disease mortality in the TAMRISK study, a 28-year follow-
up. Prev Med. 2009; 49: 45-7. 
70 Tsai AW, Cushman M, Rosamond WD, Heckbert SR, Polak JF, Folsom AR. 
Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal 
investigation of thromboembolism etiology. Arch Intern Med. 2002; 162: 1182-9. 
! 28 
71 Vaya A, Mira Y, Martinez M, Villa P, Ferrando F, Estelles A, Corella D, Aznar J. 
Biological risk factors for deep vein trombosis. Clin Hemorheol Microcirc. 2002; 26: 
41-53. 
72 Braekkan SK, Mathiesen EB, Njolstad I, Wilsgaard T, Hansen JB. Hematocrit and 
risk of venous thromboembolism in a general population. The Tromso study. 
Haematologica. 2010; 95: 270-5. 
73 Crowl LM, Fogelson AL. Computational model of whole blood exhibiting lateral 
platelet motion induced by red blood cells. Int J Numer Method Biomed Eng. 2010; 
26: 471-87. 
74 Atici AG, Kayhan S, Aydin D, Yilmaz YA. Plasma viscosity levels in pulmonary 
thromboembolism. Clin Hemorheol Microcirc. 2013; 55: 313-20. 
75 Lionnet F, Hammoudi N, Stojanovic KS, Avellino V, Grateau G, Girot R, Haymann 
JP. Hemoglobin sickle cell disease complications: a clinical study of 179 cases. 
Haematologica. 2012; 97: 1136-41. 
76 Booth S, Chohan S, Curran JC, Karrison T, Schmitz A, Utset TO. Whole blood 
viscosity and arterial thrombotic events in patients with systemic lupus erythematosus. 
Arthritis Rheum. 2007; 57: 845-50. 
77 Carvalho FA, Connell S, Miltenberger-Miltenyi G, Pereira SV, Tavares A, Ariens RA, 
Santos NC. Atomic force microscopy-based molecular recognition of a fibrinogen 
receptor on human erythrocytes. ACS Nano. 2010; 4: 4609-20. 
78 De Oliveira S, Vitorino de Almeida V, Calado A, Rosario HS, Saldanha C. Integrin-
associated protein (CD47) is a putative mediator for soluble fibrinogen interaction 
with human red blood cells membrane. Biochim Biophys Acta. 2012; 1818: 481-90. 
79 Hermand P, Huet M, Callebaut I, Gane P, Ihanus E, Gahmberg CG, Cartron JP, 
Bailly P. Binding sites of leukocyte beta 2 integrins (LFA-1, Mac-1) on the human 
ICAM-4/LW blood group protein. J Biol Chem. 2000; 275: 26002-10. 
80 Ihanus E, Uotila L, Toivanen A, Stefanidakis M, Bailly P, Cartron JP, Gahmberg CG. 
Characterization of ICAM-4 binding to the I domains of the CD11a/CD18 and 
CD11b/CD18 leukocyte integrins. Eur J Biochem. 2003; 270: 1710-23. 
! 29 
81 Hermand P, Gane P, Huet M, Jallu V, Kaplan C, Sonneborn HH, Cartron JP, Bailly P. 
Red cell ICAM-4 is a novel ligand for platelet-activated alpha IIbbeta 3 integrin. J 
Biol Chem. 2003; 278: 4892-8. 
82 Spring FA, Parsons SF, Ortlepp S, Olsson ML, Sessions R, Brady RL, Anstee DJ. 
Intercellular adhesion molecule-4 binds alpha(4)beta(1) and alpha(V)-family integrins 
through novel integrin-binding mechanisms. Blood. 2001; 98: 458-66. 
83 Barr JD, Chauhan AK, Schaeffer GV, Hansen JK, Motto DG. Red blood cells 
mediate the onset of thrombosis in the ferric chloride murine model. Blood. 2013; 
121: 3733-41. 
84 An X, Schulz VP, Li J, Wu K, Liu J, Xue F, Hu J, Mohandas N, Gallagher PG. 
Global transcriptome analyses of human and murine terminal erythroid differentiation. 
Blood. 2014; 123: 3466-77. 
85 Santos MT, Valles J, Marcus AJ, Safier LB, Broekman MJ, Islam N, Ullman HL, 
Eiroa AM, Aznar J. Enhancement of platelet reactivity and modulation of eicosanoid 
production by intact erythrocytes. A new approach to platelet activation and 
recruitment. J Clin Invest. 1991; 87: 571-80. 
86 Silvain J, Pena A, Cayla G, Brieger D, Bellemain-Appaix A, Chastre T, Vignalou JB, 
Beygui F, Barthelemy O, Collet JP, Montalescot G. Impact of red blood cell 
transfusion on platelet activation and aggregation in healthy volunteers: results of the 
TRANSFUSION study. Eur Heart J. 2010; 31: 2816-21. 
87 Silvain J, Abtan J, Kerneis M, Martin R, Finzi J, Vignalou JB, Barthelemy O, 
O'Connor SA, Luyt CE, Brechot N, Mercadier A, Brugier D, Galier S, Collet JP, 
Chastre J, Montalescot G. Impact of Red Blood Cell Transfusion on Platelet 
Aggregation and Inflammatory Response in Anemic Coronary and Non-Coronary 
Patients The TRANSFUSION-2 study. J Am Coll Cardiol. 2013. 
88 Valles J, Santos MT, Aznar J, Martinez M, Moscardo A, Pinon M, Broekman MJ, 
Marcus AJ. Platelet-erythrocyte interactions enhance alpha(IIb)beta(3) integrin 
receptor activation and P-selectin expression during platelet recruitment: down-
regulation by aspirin ex vivo. Blood. 2002; 99: 3978-84. 
89 Setty BN, Rao AK, Stuart MJ. Thrombophilia in sickle cell disease: the red cell 
connection. Blood. 2001; 98: 3228-33. 
! 30 
90 Peyrou V, Lormeau JC, Herault JP, Gaich C, Pfliegger AM, Herbert JM. Contribution 
of erythrocytes to thrombin generation in whole blood. Thromb Haemost. 1999; 81: 
400-6. 
91 Horne MK, 3rd, Cullinane AM, Merryman PK, Hoddeson EK. The effect of red 
blood cells on thrombin generation. Br J Haematol. 2006; 133: 403-8. 
92 Whelihan MF, Zachary V, Orfeo T, Mann KG. Prothrombin activation in blood 
coagulation: the erythrocyte contribution to thrombin generation. Blood. 2012; 120: 
3837-45. 
93 Van Der Meijden PE, Van Schilfgaarde M, Van Oerle R, Renne T, ten Cate H, 
Spronk HM. Platelet- and erythrocyte-derived microparticles trigger thrombin 
generation via factor XIIa. J Thromb Haemost. 2012; 10: 1355-62. 
94 Jy W, Johansen ME, Bidot C, Jr., Horstman LL, Ahn YS. Red cell-derived 
microparticles (RMP) as haemostatic agent. Thromb Haemost. 2013; 110: 751-60. 
95 Zecher D, Cumpelik A, Schifferli JA. Erythrocyte-derived microvesicles amplify 
systemic inflammation by thrombin-dependent activation of complement. 
Arterioscler Thromb Vasc Biol. 2014; 34: 313-20. 
96 Gersh KC, Nagaswami C, Weisel JW. Fibrin network structure and clot mechanical 
properties are altered by incorporation of erythrocytes. Thromb Haemost. 2009; 102: 
1169-75. 
97 Wohner N, Sotonyi P, Machovich R, Szabo L, Tenekedjiev K, Silva MM, Longstaff 
C, Kolev K. Lytic resistance of fibrin containing red blood cells. Arterioscler Thromb 
Vasc Biol. 2011; 31: 2306-13. 
98 van Gelder JM, Nair CH, Dhall DP. The significance of red cell surface area to the 
permeability of fibrin network. Biorheology. 1994; 31: 259-75. 
99 Liang XM, Han SJ, Reems JA, Gao D, Sniadecki NJ. Platelet retraction force 
measurements using flexible post force sensors. Lab Chip. 2010; 10: 991-8. 
100 Wufsus AR, Rana K, Brown A, Dorgan JR, Liberatore MW, Neeves KB. Elastic 
behavior and platelet retraction in low- and high-density fibrin gels. Biophys J. 2015; 
108: 173-83. 
! 31 
101 Sutton JT, Ivancevich NM, Perrin SR, Jr., Vela DC, Holland CK. Clot retraction 
affects the extent of ultrasound-enhanced thrombolysis in an ex vivo porcine 
thrombosis model. Ultrasound Med Biol. 2013; 39: 813-24. 
 
 
! 32 
 
 
 
Chapter 2: The fibrinogen γA/γ’ isoform does not promote acute arterial 
thrombosis in mice2 
 
2.1 Introduction 
Fibrinogen is a 340 kDa glycoprotein that circulates in plasma at 2-4 mg/mL, but 
during acute inflammation can exceed 7 mg/mL.  Fibrinogen is composed of two sets of three 
polypeptide chains: Aα, Bβ, and γ.  Alternative splicing of the main γA chain leads to the γ’ 
chain.  Molecules containing the γ’ chain circulate as a heterodimer with the γA chain (2Aα, 
2Bβ, and γA/ γ’) and comprise 8-15% of total fibrinogen in healthy individuals [1, 2].  
Elevated fibrinogen levels are associated with increased risk of arterial thrombosis [3-5], and 
we previously showed that when mice are infused with unfractionated human fibrinogen 
(~90% γA/γA and 10% γA/γ’) and subjected to FeCl3-mediated carotid artery injury, elevated 
plasma fibrinogen shortens the time to vessel occlusion [6].  These findings suggest elevated 
fibrinogen is a causative, etiologic agent in arterial thrombosis.  However, the specific 
contributions of γA/γA and γA/γ’ fibrinogen isoforms to thrombosis in vivo are unknown.   
In vitro studies to define the biochemical role of the γ’ chain have shown that clots 
made with purified γA/γ’ fibrinogen polymerize at a slower rate than clots made with 
purified γA/γA fibrinogen [7].  Additionally, the γ’ chain supports high affinity binding to 
thrombin exosite II [8, 9], and studies have shown that thrombin binding to the γ’ chain 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
2!This chapter is based on and reproduced in part with permission from: 
Walton BL, Getz TM, Bergmeier W, Lin FC, Uitte de Willige S, Wolberg AS.  
The fibrinogen γA/γ’ isoform does not promote acute arterial thrombosis in mice. J Thromb 
Haemost. 2014, 12:680-689 
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competitively inhibits thrombin-mediated platelet activation [10] and reduces thrombin-
mediated FpB cleavage [7], and factor VIII [11] and V [12] activation.  These properties 
suggest γA/γ’ fibrinogen has anticoagulant activity in vitro.  Conversely, the γ’ chain does 
not inhibit thrombin-mediated cleavage of FpA [7, 13], and has been reported to support 
higher affinity binding of FXIII than the γA chain [14], although more recent studies suggest 
only slightly tighter [14], or even similar [15], binding of FXIII to the γA/γ’ isoform 
compared to the γA/γA isoform.  Additional studies in purified systems report contradictory 
effects of the γ’ chain on clot structure and mechanical properties, demonstrating that the γ’ 
chain induces the formation of alternately smaller [7, 13, 16] or larger [17] pores, and stiffer 
[18] or less stiff [17] clots.  These conflicting observations make it difficult to predict the role 
of γA/γ’ fibrinogen under physiologic conditions in thrombosis in vivo. 
The role of the human γ’ chain in thrombosis has previously been tested in two in 
vivo studies.  Since the murine γ’ chain does not contain the thrombin-binding sequence 
found on the human γ’ chain, Mossesson et al. developed a transgenic mouse that replaced 
the murine γ’ chain with the human γ’ chain [19].  Following electrolytic injury to the 
femoral vein, there was no difference in thrombus volume between mice containing the 
human γ’ chain and wild type (WT) controls, although the presence of the human γ’ chain 
reduced thrombus volume in mice that were also heterozygous for the factor V Leiden 
mutation [19].  However, interpretation of these findings is complicated by the higher total 
fibrinogen in WT mice compared to mice expressing the human γ’ chain.  In a baboon model 
in which an arteriovenous shunt was placed between the femoral artery and vein, an 18 
amino acid peptide mimicking the γ’ chain C-terminus (γ’ 410-427) inhibited fibrin-rich 
! 34 
thrombus formation [11].  These studies suggest the γ’ chain reduces fibrin accumulation and 
is antithrombotic during venous thrombosis. 
 Given these findings, it is interesting that retrospective epidemiological studies have 
correlated elevated γA/γ’ fibrinogen levels with increased incidence of coronary artery 
disease [20], myocardial infarction [21], and stroke [22-24].  In particular, the finding that 
some patients have an increased γ’-to-total fibrinogen ratio [22-25] indicates γA/γ’ 
fibrinogen is not merely a biomarker of increased total fibrinogen, and suggests a specific 
role for γA/γ’ in arterial thrombosis.  However, these studies do not and cannot demonstrate 
causality of γ’ chain-containing fibrinogen in thrombosis.  The objective of our study was to 
determine the contribution of γA/γA and γA/γ’ fibrinogen to arterial thrombosis. 
 
2.2 Materials and Methods 
 
2.2.1 Proteins and Materials.   
Polyclonal rabbit anti-human fibrinogen antibody was from DAKOCytomation 
(Carpinteria, CA).  Monoclonal anti-fibrin(ogen) antibody (59D8) was a generous gift of Drs. 
Marschall Runge (University of North Carolina), Charles Esmon (Oklahoma College of 
Medicine), and Rodney Camire (University of Pennsylvania).  Mouse anti-human γ’ chain-
specific antibody (2.G2.H9) was from Millipore (Temecula, CA).  Biotinylated secondary 
antibodies were from Vector Laboratories (Burlingame, CA).  The AlexaFluor-488 protein 
labeling kit and 10% pre-cast Tris-glycine gels were from Invitrogen (Carlsbad, CA).  
Human α-thrombin and murine thrombin were from Enzyme Research Laboratories (South 
Bend, IN).  Lipidated tissue factor (TF, Innovin) was from Siemens (Newark, DE).  
Phospholipid vesicles (phosphatidylserine/phosphatidylcholine/phosphatidylethanolamine) 
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were prepared as described [26].  Bovine serum albumin was from Sigma-Aldrich (St. Louis, 
MO).  Peroxidase substrate was from KPL (Gaithersburg, MD).  
 
2.2.2 Plasma preparation.   
Contact-inhibited human normal pooled plasma (hNPP) was prepared from 40 
healthy subjects (50% female, 68% nonwhite) as described [27], in a protocol approved by 
the UNC Institutional Review Board.  γA/γ’ fibrinogen levels in hNPP were measured by 
ELISA, as described [28].  Murine normal pooled plasma (mNPP) was prepared by 
collecting blood from 49 female C57Bl/6 mice by inferior vena cava (IVC) venipuncture into 
3.2% sodium citrate (1:9 ratio sodium citrate:blood).  Pooled whole blood was centrifuged 
(4000xg, 20 minutes), and platelet-poor plasma was aliquoted and frozen at -80oC. 
 
2.2.3 Isolation of γA/γA and γA/γ’ fibrinogen.   
The γA/γA and γA/γ’ fibrinogen variants were separated from human plasminogen-, 
von Willebrand Factor-, and fibronectin-depleted human fibrinogen (Enzyme Research 
Laboratories Ltd., Swansea, UK), based on the method described previously [7].  After 
purification, variants were concentrated using Vivaspin 20 MWCO 100,000 columns (GE 
Healthcare, Uppsala, Sweden) and dialyzed into 20 mM N-2-hydroxyethylpiperazine-N′-2-
ethanesulfonic acid (pH 7.4) containing 150 mM NaCl (HBS).  Fibrinogen concentration was 
determined by absorbance at 280 nm using an extinction coefficient of 1.51 mL/(mg/cm).  
Both variants were functionally active (>95%) in a standard clotability assay. 
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2.2.4 SDS-PAGE and western blotting.   
Fibrinogen preparations were assessed by 10% SDS-PAGE and Coomassie Brilliant 
Blue staining or western blotting for total fibrinogen or fibrinogen γ’ chain.  For western 
blots, membranes were blocked with Tris-buffered saline with 1% Tween containing 5% 
milk, washed, and probed sequentially with mouse-anti human γ’-specific primary antibody 
and AlexaFluor-488 conjugated anti-mouse secondary antibody.  Fluorescent signal was 
detected on a Typhoon 900 FLA fluorescent scanner.  
 
2.2.5 Clot formation with purified fibrin(ogen).   
Purified fibrinogen, thrombin, and CaCl2 (0.5 mg/mL, 5 nM, and 10 mM, final, 
respectively) were combined in 96-half-well plates and polymerization was monitored by 
turbidity at 405 nm using SpectraMax Plus340 plate reader (Molecular Devices, Sunnyvale, 
CA).  
 
2.2.6 Clot formation in plasma.   
hNPP or mNPP was spiked with HBS (Control), or γA/γA or γA/γ’ fibrinogen, and 
clotting was initiated with TF (1:30,000 dilution of Innovin, final), 10 mM CaCl2, and 4 µM 
phospholipid vesicles in 96-well plates.  Clot formation was monitored by turbidity at 405 
nm. 
 
2.2.7 Intravital microscopy.   
Procedures were approved by the UNC Institutional Animal Care and Use Committee.  
Laser-induced thrombosis to cremaster muscle venules was performed as described [29].  
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Briefly, 6-8 week old male C57Bl/6 mice (Charles River Laboratories, Wilmington, MA) 
were anesthetized and laser injuries were induced with an Ablate! photoablation system 
equipped with an attenuatable 532 nm pulse laser (Intelligent Imaging Innovations, Denver, 
CO).  Five minutes before injury, mice were injected via the retro-orbital plexus with 
AlexaFluor 595-labeled anti-glycoprotein IX antibody (0.3 mg/g body weight; Emfret, 
Eibelstadt, Germany), and AlexaFluor 647-labeled murine anti-fibrin antibody (0.2 mg/g 
body weight), and trace amounts (5% of total fibrinogen) of AlexaFluor 488-labeled γA/γA 
or γA/γ’ fibrinogen.  Five venules maximum were studied per mouse.  
 
2.2.8 FeCl3 thrombosis model.   
FeCl3 injury to carotid arteries was performed as described [6].  Briefly, 6-8 week old 
male C57Bl/6 mice were anesthetized, and human fibrinogen or vehicle (HBS) was 
administered through the left saphenous vein cannula on a per-weight basis 5 minutes before 
injury.  The right common carotid artery was exposed, dried and treated with FeCl3 (10% on 
0.5×1.0-mm filter paper) for 2 minutes.  We specifically titrated the conditions to perform 
these experiments at a threshold at which some mice do not form thrombi, to allow for 
sensitivity to both increased and decreased procoagulant activity.  Blood flow was monitored 
by Doppler ultrasonic flow probe, and the time to occlusion (TTO) was defined as the time 
between FeCl3 administration and lack of flow for 60 consecutive seconds, as previously 
described [6]. 
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2.2.9 Measurement of circulating TAT complexes.   
TAT levels were measured by ELISA (Enzygnost TAT micro ELISA, Siemens) using 
plasma prepared from IVC blood draws from mice subject to FeCl3 carotid artery thrombosis 
(blood was drawn ~5 minutes following vessel occlusion).  Samples showing hemolysis were 
excluded.  
 
2.2.10 Statistical Methods.   
Descriptive statistics (mean, median, standard deviation [SD], standard error of the 
mean [SEM]) were calculated.  Groups were compared using Student’s t-tests (normally-
distributed data determined by Lilliefors test for normality) or Wilcoxon-Mann-Whitney 
Rank Sum Tests (non-normally distributed data) in Kaleidagraph v4.1.3.  Correlations were 
performed using SAS 9.2 (SAS Inc., Cary, NC).  P<0.05 was considered statistically 
significant. 
 
2.3 Results 
 
2.3.1 γA/γA fibrinogen increases the fibrin polymerization rate to a greater extent than 
γA/γ’ fibrinogen.   
Purified γA/γA fibrinogen contained all three fibrinogen chains (Aα, Bβ, and γ) at 
expected molecular weights (Figures 2.1A-B).  No γ’ chain was detected in γA/γA fibrinogen 
(Figure 2.1C), whereas purified γA/γ’ fibrinogen showed equal intensities of γA and γ’ bands 
(Figures 2.1A-B).  We first clotted purified fibrinogens with purified human thrombin and 
followed clotting by turbidity.  Although fibrinogen γA/γA and γA/γ’ isoforms were not 
explicitly depleted of FXIII, Allen et al. previously showed that the presence or absence of 
! 39 
FXIII does not affect differences in polymerization between γA/γA and γA/γ’ fibrinogen [17].  
Indeed, consistent with previous reports [7, 13, 17], purified γA/γA exhibited a faster 
polymerization rate (2.7-fold, P<0.05) and higher final turbidity (1.5-fold, P<0.05) than 
purified γA/γ’ (Figure 2.1D, Table 2.1).  Findings were similar when murine thrombin was 
used (Figure 2.1D, Table 2.1), showing murine thrombin can convert human fibrinogen to 
fibrin. 
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Figure 2.1.  Purified fibrinogen contains all three chains (Aα, Bβ, and γA and/or γ’) at 
the expected molecular weights and is equally cleaved by human and mouse thrombin.  
Unfractionated (UF), or purified γA/γA, or γA/γ’ fibrinogen were reduced and separated by 
10% SDS-PAGE and detected by:  A) Coomassie Brilliant Blue staining, B) polyclonal anti-
fibrin(ogen) antibody, or C) 2.G2.H9 antibody against the γ’ chain.  D) Purified human 
γA/γA (squares) or γA/γ’ (diamonds) fibrinogen was clotted in the presence of CaCl2 and 
human (closed symbols) or murine (open symbols) thrombin.   Data show mean±SD, for 
experiments with human (n=3) and mouse (n=2) thrombin.   
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Table 2.1.  Polymerization of purified fibrinogen isoforms by human and murine 
thrombin 
 Human Thrombin Murine Thrombin 
 Lagtime (seconds) 
Change in 
Turbidity 
(OD) 
Vmax 
(mOD/min) 
Lagtime 
(seconds) 
Change in 
Turbidity 
(OD) 
Vmax 
(mOD/min) 
γA/γA 14.2±4.7 0.222±0.022 179.6±16.5 8.25±4.9 0.214±0.024 208.7±38.4 
γA/γ’ 13.7±5.0 0.149±0.016# 66.3±6.5# 6.25±6.2 0.164±0.012# 61.1±14.7# 
 Mean±SD, #P<0.05 versus γA/γA 
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To determine the effect of elevated γA/γA and γA/γ’ fibrinogen on plasma clot 
formation during in situ thrombin generation, we spiked purified γA/γA, γA/γ’, or HBS 
(control) into hNPP.  The concentration of fibrinogen in hNPP was 3.1±0.1 mg/mL (100%) 
and baseline concentration of γA/γ’ fibrinogen in hNPP was 0.42 mg/mL (13.5% of total 
fibrinogen).  We increased the total fibrinogen concentration to 3.5 (114%), 3.9 (127%), or 
4.4 (143%) mg/mL by spiking in purified γA/γA or γA/γ’, so that the γA/γ’-to-total 
fibrinogen ratios ranged from 9.6-40.1% (Table 2.2).  These levels span the range of γA/γ’ 
levels measured in healthy individuals and patients with thrombosis [23-25, 30, 31].  
Elevating either γA/γA or γA/γ’ fibrinogen increased final clot turbidity compared to plasma 
spiked with HBS (Figure 2.2B, Table 2.2).  When total fibrinogen was raised to 114%, 
neither γA/γA nor γA/γ’ fibrinogen increased the clot formation rate.  However, elevating 
total fibrinogen to 127% or 143% with γA/γA or γA/γ’ significantly and dose-dependently 
increased the clot formation rate versus baseline (HBS).  Notably, at each concentration, 
elevating total fibrinogen with γA/γA increased the clot formation rate to a significantly 
greater extent than elevating total fibrinogen with γA/γ’ (Figure 2.2C, Table 2.2).  Linear 
regression analysis showed that the clot formation rate correlated positively with elevated 
total fibrinogen (r=0.667, P<0.001) and negatively with the γ’-to-total fibrinogen ratio (r=-
0.0245, P=0.17), although the relationship between γ’-to-total and clot formation rate did not 
reach significance.  Moreover, the level of γA/γA isoform correlated strongly with the clot 
formation rate (r=0.795, P<0.001) whereas the level of γA/γ’ did not. 
Spiking purified human γA/γA, γA/γ’, or HBS (Control) into mNPP produced similar 
results.  For these experiments, the fibrinogen concentration in mNPP was 2.4±0.2 mg/mL 
(100%), and we spiked mNPP to 3.2 (135%) and 4.1 mg/mL (170%) with γA/γA or γA/γ’, 
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yielding human γ’-to total fibrinogen ratios ranging from 0-41.2%.  Consistent with previous 
observations [6], the final turbidity of murine plasma clots was lower than that of human 
plasma clots, likely reflecting increased fibrin density of murine fibrin networks versus 
human networks (unpublished observation).  As in human plasma, both γA/γA and γA/γ' 
increased the clot formation rate, but γA/γA increased the rate to a greater extent than γA/γ' 
at each concentration tested (P<0.02, Figure 2.2F, Table 2.3).  These findings suggest that 
during in situ thrombin generation, both elevated γA/γA and γA/γ’ fibrinogen promote clot 
formation, but γA/γA does so to a greater extent.  
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Figure 2.2.  Both γA/γA and γA/γ’ fibrinogen accelerate clotting in human and mouse 
plasma.  A-C) hNPP was spiked with γA/γA or γA/γ’ to increase total fibrinogen to 114%, 
127%, or 143% of normal (symbols appear in figure legend), and clot formation was 
triggered by addition of TF and CaCl2.  D-F) mNPP was spiked with human γA/γA or γA/γ’ 
to increase total fibrinogen to 135% or 170% of normal (symbols appear in figure legend) 
and clot formation was triggered by addition of TF and CaCl2.  A, D) Polymerization was 
monitored by turbidity; for clarity, only a subset of points is shown.  B, C, E, F) The 
contribution of increasing total fibrinogen with γA/γA (solid bars) or γA/γ’ (striped bars) on 
final turbidity (B, E) and fibrin formation rate (C, F) in human (B, C) and mouse (E, F) 
plasma.  Dashed lines represent final turbidity and clot formation rate of HBS controls.  Data 
show means, n=3.  *p<0.05 versus HBS; #p<0.05 versus γA/γA. 
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Table 2.2. Effect of fibrinogen isoforms on human plasma clotting 
Total 
Fibrin-
ogen 
(mg/mL 
[% ]) 
Fibrin-
ogen/ 
Buffer 
Infused 
Human 
γA/γ’ 
Final 
(mg/mL) 
Human 
γ’-to-
Total 
Ratio 
(%) 
Lagtime 
(minutes) 
Change in 
Turbidity 
(OD) 
Vmax 
(mOD/min) 
3.1 
(100%) 
HBS 0.4 13.5 9.7±3.0 0.587±0.034 54.8±9.3 
3.5 
(114%) 
γA/γA 0.4 11.9 9.7±1.5 0.715±0.007* 62.5±5.7 
3.5 
(114%) 
γA/γ’ 0.8 23.9 8.7±0.6 0.690±0.016* 54.3±5.8 
3.9 
(127%) 
γA/γA 0.4 10.7 8.7±1.9 0.789±0.032* 171.7±67.1* 
3.9 
(127%) 
γA/γ’ 1.3 32.0 10.0±3.4 0.755±0.043* 98.2±19.9*,# 
4.4 
(143%) 
γA/γA 0.4 9.6 8.5±1.1 0.844±0.022* 263.9±56.6* 
4.4 
(143%) 
γA/γ’ 1.8 40.1 10.1±13.5 0.784±0.016*,# 100.4±13.5*,# 
Mean±SD, *P<0.05 versus HBS; #P<0.04 versus γA/γA (at same total fibrinogen) 
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Table 2.3. Effect of fibrinogen isoforms on mouse plasma clotting 
Total 
Fibrin-
ogen 
(mg/mL 
[%]) 
Fibrinogen/ 
Buffer 
Infused 
Human 
γA/γ’ 
Final 
(mg/mL) 
Human 
γ’-to-
Total 
Ratio 
(%) 
Lagtime 
(minutes) 
Change in 
Turbidity 
(OD) 
Vmax 
(mOD/min) 
2.4 
(100%) 
HBS 0 0 4.0±0.3 0.111±0.003 28.0±2.5 
3.2 
(135%) 
γA/γA 0 0 3.5±0.3 0.222±0.016* 73.3±8.9* 
3.2 
(135%) 
γA/γ’ 0.8 25.9 4.0±0.4 0.184±0.023* 47.4±5.0*,# 
4.1 
(170%) 
γA/γA 0 0 4.0±0.3 0.350±0.015* 126.7±4.6* 
4.1 
(170%) 
γA/γ’ 1.7 41.2 4.1±0.2 0.265±0.012*,# 66.2±5.2*,# 
 Mean±SD, *P<0.03 versus HBS; #P<0.02 versus γA/γA (at same total fibrinogen) 
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2.3.2 Both γA/γA and γA/γ’ fibrinogen are incorporated into murine thrombi in vivo.   
Drouet et al. previously suggested that an increased γ’-to-total fibrinogen ratio is 
detected in patient plasmas because γA/γA is incorporated into platelet thrombi, whereas 
γA/γ’ is not [25].  Therefore, we determined whether γA/γ’ was incorporated into thrombi in 
vivo.  We infused mice with AlexaFluor 594-labeled anti-platelet (anti-GPIX) antibody, 
AlexaFluor 647-labeled antibody against fibrin(ogen) (59D8), and trace amounts (5% of total 
fibrinogen) of fluorescently-labeled γA/γA or γA/γ’ fibrinogen.  We then triggered vascular 
injury to the cremaster vessels and detected γA/γA or γA/γ’ fibrinogen within thrombi using 
intravital microscopy.  We initially performed this experiment with arterioles, but observed 
substantial vessel constriction in response to the injury.  However, the venule provided a 
reasonable alternative that enabled us to avoid the issue of vasoconstriction while observing 
platelet and fibrin(ogen) accumulation at the injury site in vivo.  Figure 2.3 shows that both 
γA/γA and γA/γ’ isoforms were incorporated into murine thrombi in vivo. 
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Figure 2.3.  Intravital microscopy shows both γA/γA and γA/γ’ isoforms are 
incorporated into murine thrombi.  Venules were visualized in the cremaster muscle of 
mice infused with HBS (control) or AlexaFluor 594-labeled anti-platelet (anti-GPIX) 
antibody, AlexaFluor 647-labeled anti-fibrin antibody, and purified γA/γA or γA/γ’ directly 
labeled with AlexaFluor 488.  Thrombosis was triggered via laser injury.  Flow is indicated 
by white arrows.  Colors are:  platelets (red), fibrin(ogen) (green), and fibrin (blue).  In the 
merged image, colors are:  platelets plus fibrin(ogen) (pink), platelets plus fibrin (purple), 
and fibrin(ogen) plus fibrin (teal).  Images show representative thrombi from 3-4 mice with 
14-20 injuries total.  
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2.3.3 Following FeCl3 injury, γA/γA, but not γA/γ’, fibrinogen shortens the time to 
artery occlusion.   
To determine the effect of elevated circulating γA/γA and γA/γ’ fibrinogen on arterial 
thrombosis, we infused mice with HBS or purified human γA/γA, γA/γ’, or unfractionated 
fibrinogen and induced thrombosis via FeCl3 application to the carotid artery.  Both human 
and mouse fibrinogen can be cleaved by human and murine thrombin, cross-linked by factor 
XIIIa, and digested by plasmin [32].  Additionally, human fibrinogen circulates in mouse 
plasma, and is incorporated into murine thrombi (Figure 2.3, [6, 33-35]).  For these 
experiments, we obtained total fibrinogen levels of 135% and 170% of normal levels, with 
human-γ’-to-total fibrinogen ratios of 0%, 25.9%, and 41.2%, consistent with ratios found in 
normal and pathological conditions [23-25, 30, 31, 36]. 
Consistent with previous findings, following FeCl3 injury, there was no significant 
difference in TTO between control mice or mice infused to 135% mg/mL total fibrinogen 
with either γA/γA or γA/γ’ (data not shown) [6].  When total fibrinogen was raised to 170% 
with γA/γA fibrinogen, the median TTO was faster than that of mice infused with HBS 
(5.48±0.50 versus 7.25±3.03 minutes [median±SEM], P<0.05, Figure 2.4A), similar to that 
seen in mice infused with unfractionated fibrinogen.  However, raising the level of fibrinogen 
to 170% with γA/γ’ fibrinogen did not shorten the median TTO compared to controls (Figure 
2.4A).  Moreover, 7.25 minutes after FeCl3 injury, 100% and 86% of mice infused with 
unfractionated or γA/γA fibrinogen, respectively, had an occluded vessel, whereas only 50% 
of mice infused with γA/γ’ fibrinogen developed vessel occlusion (Figure 2.4B).  Together, 
these data indicate that elevated γA/γA fibrinogen promotes arterial thrombosis, whereas 
elevated γA/γ’ does not.  
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Figure 2.4.  γA/ γA fibrinogen shortens the time to vessel occlusion after arterial injury, 
but γA/γ’ does not.  Mice were infused with HBS, unfractionated (UF), γA/γA, or γA/γ’ 
fibrinogen to 170%, total fibrinogen.  Thrombosis was induced by FeCl3 application to the 
carotid artery and TTO was determined by Doppler flow probe.  In vessels that did not 
occlude, the TTO was recorded as 40 minutes.  A) Each point represents a separate mouse.  
Lines indicate median values, *p<0.05 versus HBS.  B) Percent of mice occluded at 7.25 
minutes (the median TTO of HBS-infused mice), using the data from (A); 100%, 86%, and 
50% of UF-, γA/γA-, and γA/γ’-infused mice, respectively, had occluded vessels at this time.   
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2.3.4 Following FeCl3 injury, mice infused with γA/γ’ fibrinogen have lower circulating 
TAT complexes than mice infused with γA/γA fibrinogen.   
The γ’ chain supports high affinity binding to thrombin exosite II [8, 9], and prior 
studies have shown that γA/γ’ fibrinogen has anticoagulant properties (antithrombin I 
activity) in vitro [10-12].  To determine the effect of γA/γ’ on procoagulant activity in vivo, 
we measured TAT complexes in murine plasma following FeCl3 injury and stable vessel 
occlusion.  Whereas mice infused with unfractionated or γA/γA fibrinogen had similar 
circulating TAT complexes as HBS-infused mice, mice infused with γA/γ’ had significantly 
lower circulating TAT complexes (6.2±8.4 versus 18.9±10.9 ng/mL [median±SEM] for γA/γ’ 
and HBS-infused mice, respectively, P<0.01, Figure 2.5), consistent with the concept that 
thrombin binding to γA/γ’ fibrinogen sequesters thrombin [10-12, 37] and protects it from 
inhibition by antithrombin.  These findings suggest γA/γ’ fibrinogen binds and sequesters 
thrombin in vivo and limits thrombin activity following vascular injury. 
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Figure 2.5.  Following arterial injury, mice infused with γA/γ’ fibrinogen have reduced 
circulating TAT complexes.  TAT levels were measured in plasmas collected from mice 
subjected to the FeCl3 carotid artery thrombosis.  Box plots indicate medians and upper and 
lower quartiles, *p<0.05 versus HBS. 
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2.4 Discussion 
Although epidemiologic studies have associated elevated plasma fibrinogen with 
arterial thrombosis [3-5], the operant pathogenic mechanisms have been controversial.  We 
previously showed that increased total plasma fibrinogen directly promotes arterial 
thrombosis in mice [6].  Herein, we separately tested the role of γA/γA and γA/γ’ fibrinogen 
and show that both elevated γA/γA and γA/γ’ increased the plasma clot formation rate, but 
that γA/γA increased the rate to a greater extent than γA/γ’.  Although both γA/γA and γA/γ’ 
fibrinogen were incorporated into murine clots, γA/γA fibrinogen shortened the TTO, 
whereas γA/γ’ did not.  Interestingly, compared to controls, mice infused with γA/γ’ 
fibrinogen had lower levels of circulating plasma TAT complexes following arterial injury, 
whereas mice infused with γA/γA did not, suggesting that γA/γ’ fibrinogen binds and 
sequesters thrombin in vivo.  Together, our data indicate that γA/γ’ fibrinogen is not 
prothrombotic in vivo and may even have a protective role in preventing elevated total 
fibrinogen levels from promoting thrombosis. 
Our data support the premise that γA/γ’ fibrinogen has both procoagulant and 
anticoagulant properties and exhibits both of these activities during thrombosis in vivo.  
Similar to γA/γA fibrinogen, γA/γ’ increased the fibrin formation rate and final turbidity, 
though to a lesser extent than γA/γA.  Consequently, increased total fibrinogen levels, via 
either increased γA/γA or γA/γ’, would be expected to promote fibrin formation.  However, 
unlike γA/γA, γA/γ’ fibrinogen exhibits antithrombin I activity in vitro [10-12, 37] and in 
vivo (Figure 2.5).  Thus, our finding that elevated γA/γA fibrinogen shortened the TTO, but 
elevated γA/γ’ did not, suggests that the net effect of γA/γ’ fibrinogen’s opposing 
procoagulant and anticoagulant activities yielded no change in the TTO (Figure 2.6).  These 
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data suggest that a peptide representing the C-terminus of the γ’ chain would have strong 
anticoagulant effects in vivo, since the procoagulant properties of the full length fibrinogen 
molecule would not be present, whereas the thrombin binding properties of the γ’ chain 
would decrease circulating thrombin.  Indeed, this effect was previously demonstrated during 
in vivo thrombosis, in which Lovely et al. saw decreased platelet and fibrin accumulation in 
the presence of γ’ chain peptide [11].   
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Figure 2.6. γA/γ’ fibrinogen binds thrombin, resulting in lower thrombin-antithrombin 
levels and similar TTO as controls. When mice were infused with γA/γA fibrinogen, 
fibrinogen was converted to fibrin by thrombin to eventually cause a shortened TTO.  In 
these mice, thrombin was inhibited by antithrombin (left).  When mice were infused with 
γA/γ’ fibrinogen, the γ’ binds to thrombin, preventing its activity from shortening the TTO, 
resulting in less thrombin bound to antithrombin (right). 
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Although previous studies have compared isolated γA/γA and γA/γ’ fibrinogens in 
purified systems, only one has done so during in situ thrombin generation in plasma.  Using 
plasmas from apparently healthy Black South Africans, Pieters et al. correlated total 
fibrinogen levels, γA/γ’ fibrinogen levels, and the γ’-to-total fibrinogen ratio with the plasma 
clot formation rate and turbidity change [38].  Their data suggest that the clot formation rate 
increases with total fibrinogen, but decreases with elevated γ’-to-total fibrinogen ratio.  Our 
data extend these findings in a system that enabled us to precisely control fibrinogen isoform 
levels and avoid variability between donor plasmas.  Consistent with Pieters et al., we found 
the clot formation rate correlated positively with elevated total fibrinogen.  Importantly, the 
level of γA/γA isoform correlated strongly with the clot formation rate, whereas the level of 
γA/γ’ did not, suggesting the increase in clot formation rate caused by elevated total 
fibrinogen is due to γA/γA fibrinogen. 
Two prior studies evaluated the effect of the γ’ chain on thrombosis in vivo.  Those 
studies were limited by differences in the total fibrinogen level expressed by WT and human 
γ’-expressing mice [19] and use of isolated γ’ peptide rather than full length γA/γ’ fibrinogen 
[11].  Moreover, Mosesson et al. [19] evaluated γA/γ’ fibrinogen in a venous thrombosis 
model, and although the arteriovenous shunt model used by Lovely et al. [11] included 
aspects of arterial thrombosis, it did not recapitulate endothelial denudation and 
subendothelial exposure associated with plaque rupture and arterial thrombus formation.  
Consequently, our study supports and extends the prior findings in several important ways.  
First, our infusion strategy enabled us to tightly-control the level of circulating γA/γA and 
γA/γ’ fibrinogen, allowing us to specifically attribute effects to the levels of isoform and total 
fibrinogen.  Second, our study demonstrated the antithrombin I properties of the full-length 
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form of the γ’ chain.  Third, our findings extend previous data from venous thrombosis to 
arterial pathology.  This extension is important since the role of γA/γ’ in arterial thrombosis 
has been controversial.  Our findings provide important evidence that γA/γA fibrinogen is 
causative in the etiology of arterial thrombosis, whereas γA/γ’ fibrinogen is not. 
Given our findings showing that γA/γ’ fibrinogen does not promote arterial 
thrombosis, it remains unclear why epidemiological studies find a positive association 
between elevated γA/γ’ fibrinogen and arterial thrombosis.  Previous studies have suggested 
that clots formed from γA/γ’ fibrinogen are more resistant to lysis, and conflicting studies 
report abnormal structure and mechanical stability in γ’-chain containing clots [7, 17, 18].  
Thus, γA/γ’ fibrinogen may produce clots with increased stability that are detected because 
they persist longer than clots that contain γA/γA.  Interestingly, hypofibrinolysis is correlated 
with increased risk of arterial thrombosis in young (<~50) [39, 40], but not older (>~50) 
individuals [41, 42], suggesting abnormal clot stability explains some, but not all, of the 
mechanisms leading to arterial thrombosis.  Future studies are warranted to determine the 
effect of the γA/γ’ isoform on arterial clot stability.   
Interestingly, Rein-Smith et al. recently showed interleukin-6 preferentially up-
regulates hepatocyte production of γA/γ’ fibrinogen compared to γA/γA [43].  These data 
suggest γA/γ’ (“antithrombin I”) expression is upregulated to limit endogenous procoagulant 
activity triggered by inflammation.  Indeed, C-reactive protein is elevated in patients with a 
history of arterial thrombosis [23], reflecting the proinflammatory pathology.  Increased γA/γ’ 
levels detected in patients after arterial thrombosis are likely a consequence of disease rather 
than cause, and reflect an innate, antithrombotic response to inflammation.  Although our 
fibrinogen infusion/acute thrombosis model enabled us to isolate and investigate the 
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immediate, direct effects of elevated γA/γA and γA/γ’ on thrombus formation, it did not 
recapitulate the inflammatory process associated with atherosclerosis.  Consequently, long-
term exposure to circulating γA/γ’ fibrinogen may have additional effects on plaque 
formation and/or stability.  Notably, however, Mosesson et al. did not report evidence of 
chronic inflammation or atherosclerosis in their model of chronically-elevated fibrinogen γ’ 
levels [19] suggesting even chronic exposure to elevated γA/γ’ fibrinogen levels does not 
cause thrombosis. 
In summary, our results show that both γA/γA and γA/γ’ fibrinogen increased the 
fibrin formation rate in plasma, but γA/γA fibrinogen accelerated the rate to a greater extent 
than γA/γ’ fibrinogen.  After arterial injury, γA/γA fibrinogen promoted thrombosis, whereas 
γA/γ’ did not.  Mice infused with γA/γ’ had lower levels of circulating TAT complexes, 
suggesting that following vascular injury, γA/γ’ fibrinogen binds thrombin in vivo and limits 
thrombin activity.  Our data establish independent roles of fibrinogen γA/γA and γA/γ’ in 
arterial thrombosis, and suggest γA/γA fibrinogen promotes thrombosis, whereas γA/γ’ 
sequesters thrombin and protects against procoagulant processes induced by inflammation. 
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Chapter 3: Elevated Hematocrit Promotes Arterial Thrombosis Independent of 
Thrombin Generation 
 
3.1 Introduction 
 Red blood cells (RBCs) are the most abundant cell type in blood.  Normal RBC levels 
range from ~ 4.2 to 6.1×109/mL in humans, with numbers being slightly higher in males than 
in females.  RBCs develop in the bone marrow, and circulate for ~120 days.  RBCs are 
primarily known for their role in oxygen transport via their hemoglobin-rich cytoplasm.       
 Despite being a major component of thrombi, RBCs have been thought to be passive 
participants in hemostatic and thrombotic processes.  However, growing evidence suggests 
RBCs directly contribute to coagulation.  Longitudinal, prospective studies have implicated 
elevated hematocrit as an independent risk factor for cardiovascular disease (CVD) and 
CVD-related deaths.  In a cohort of 2555 rural and 6151 urban men, incidence of myocardial 
infarction (MI), coronary insufficiency, or coronary heart disease (CHD) deaths were more 
than double in the high hematocrit group (hematocrit greater than 49%) compared to the low 
group (hematocrit less than 42%) [1].  Additionally, in a cohort of 2014 healthy men that 
were followed over a 16-year period, a high hematocrit was associated with increased risk of 
dying from CVD [2].  Moreover, health data were examined from 5209 men and women (age 
range 30-62) participating in the Framingham study and in a 34-year follow-up, it was 
determined that men and women in the highest hematocrit quintile (men ≥49%; women 
≥46%) had an increased risk of death from CVD [3].  More recently, Toss et al. [4] found 
that younger men (18-19 years old) with an elevated hematocrit (≥49%) had a 1.4-fold 
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increased risk of MI compared to men with lower hematocrit (≤44%) over the 36-year 
follow-up.  This relationship was linear and remained constant throughout the follow-up 
period.  
 RBC transfusion can alleviate bleeding in anemic patients [5], but is also associated with 
thrombosis in cancer patients [6], following surgery [7], and after subarachnoid hemorrhage 
[8].  In the latter study, thrombotic risk was dose-dependent with number of RBC units 
transfused and independent of unit storage time.  Moreover, a recent, large meta-analysis of 
blood transfusion following MI found that transfusion was associated with higher risk of 
mortality and subsequent MI compared to non-transfused controls [9].  These studies 
strongly associate elevated hematocrit with thrombosis.  However, it remains unclear 
whether an elevated hematocrit is directly causal in arterial thrombus formation.   
 Recent studies have documented specific properties of RBCs that may contribute to 
thrombosis.  First, RBCs express phosphotidylserine (PS) on their cell membranes [10] and 
these PS-positive surfaces support prothrombinase assembly and thrombin generation [11-
13].  Patients with prothrombotic disorders such as polycythemia vera (PV), β-thalassemia, 
and sickle cell disease (SCD), have increased numbers of circulating PS-positive RBCs [14-
16], and in patients with SCD, the number of circulating PS-positive RBCs correlates with 
prothrombin fragment 1.2, a measure of ongoing thrombin generation [17].  These data 
suggest RBC procoagulant activity supports thrombin generation in vivo.  Second, RBCs 
increase platelet reactivity.  ADP released by RBCs has been shown to activate platelets and 
this activation has been shown to be resistant to aspirin [18, 19].  These data suggest 
hematocrit may influence the therapeutic effect of aspirin.  Third, RBCs are the principle 
determinants of blood viscosity and therefore blood flow.  Blood viscosity increases 
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exponentially with a rise in the hematocrit; thus, a relatively small increase in hematocrit 
produces a logarithmic increase in viscosity [20].  For example, a rise in hematocrit from 
40% to 60% may increase blood viscosity 2.5-fold at high shear and 3.0-fold at low shear 
[20].  Increased blood viscosity reduces blood flow and is associated with increased risk of 
thrombosis [21].  Finally, hematocrit mediates the rate of platelet flux toward the vessel walls 
[22]; in the high shears of the arterial circulation, elevated hematocrit causes increased 
margination of platelets toward the vessel wall, promoting increased platelet-endothelial, 
platelet-platelet interactions and platelet activation [23].  However, it is unclear if these RBC 
properties contribute to thrombosis in vivo. 
 Herein, we determined in vitro that RBCs dose-dependently increased thrombin 
generation in the absence of platelets, but this effect is lost when platelet concentration is 
increased.  We also developed a novel in vivo model of elevated hematocrit in mice.  
Following RBC infusion, RBCHIGH mice maintained normal WBC and platelet numbers but 
had an elevated hematocrit.  When challenged with an arterial injury, RBCHIGH mice had a 
faster time to occlusion (TTO) compared to controls.  However, there was no difference in 
plasma thrombin-antithrombin (TAT) levels and thrombus fibrin content suggesting RBCs 
cause thrombosis independent of their procoagulant activity.  
 
3.2 Materials and Methods 
3.2.1 Proteins and Materials.   
 Monoclonal anti-fibrin(ogen) antibody (59D8) was a generous gift of Drs. Marschall 
Runge (University of North Carolina [UNC]), Charles Esmon (Oklahoma Medical Research 
Foundation).  Lipidated tissue factor (TF, Innovin) was from Siemens (Newark, DE).  P2Rho 
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thrombin-specific substrate was a generous gift from Dr. Bas de Laat (Synapse, Maastricht, 
Netherlands).  Calcium ionophore (A23187) is from Sigma (St. Louis, MO).  Anti-TER119 
antibody was purchased from Thermo Scientific (Waltham, MA) and anti-annexin V 
antibody was purchased from BD Pharmingen (San Jose, CA), Prostacyclin I2 (PGI2) was 
purchased from Cayman Chemical (Ann Arbor, MI).  Mineral Oil was purchased from Sigma 
(St. Louis, MO). 
 
3.2.2 Phlebotomy.  
 Phlebotomy was conducted from healthy, consenting human donors in accordance with 
the Declaration of Helsinki and the Institutional Review Board at the University of North 
Carolina.  Donors had not taken aspirin for 5 days prior to phlebotomy. Blood was collected 
via antecubital venipuncture into 0.105 M sodium citrate, pH 5.5 (10% v/v, final 
concentration).  
 
3.2.3 Reconstituted whole blood model.   
 Whole blood was centrifuged at 150xg for 20 minutes to separate the platelet-rich plasma 
(PRP), buffy coat, and the RBC fraction.  The PRP was then separated into two fractions.  
For fraction 1, PGI2 was added to PRP which was then centrifuged to produce a platelet 
pellet in platelet-poor plasma (PPP).  This PPP (containing PGI2) was discarded.  For fraction 
2, PRP was centrifuged to make PPP (without PGI2).  The PPP from fraction 2 was used to 
resuspend the platelet pellet.  The RBC fraction was further centrifuged to produce packed 
RBCs (pRBCs).  Cell counts were obtained on a Sysmex pocH-100i™  Automated 
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Hematology Analyzer (Lincolnshire, IL).  pRBCs, platelets, and PPP were combined to the 
hematocrit and platelet concentrations indicated.  
 
3.2.4 Thrombin generation in whole blood.   
 Thrombin generation was measured in whole blood as described [24].  Briefly, 30 µL of 
reconstituted blood was mixed with 10 µL thrombin specific substrate (P2Rho; 1.8 mM).  
Clotting was activated with 20 µL of tissue factor and CaCl2 (1.5 pM and 50 mM, 
respectively).  A 5 µL aliquot of the clotting reactions was immediately transferred to a 96-
well plate containing Whatman 589/1 filter paper (St. Louis, MO) and covered with 40 µL of 
mineral oil.  Calibration wells were run for each hematocrit using 20 µL of α2M-thrombin.  
Fluorescence was recorded every 5 seconds with a Fluoroskan Ascent microplate fluorometer 
with λex = 485 nm and λem = 538 nm.  Reactions were performed at 37 oC. 
 
3.2.5 Mouse model of elevated hematocrit.   
 Procedures were approved by the UNC Institutional Animal Care and Use Committee.  
RBCs were harvested from healthy, 6- to 8-week old male and female C57Bl/6 mice.  Briefly, 
mice were anesthetized and blood was drawn from the inferior vena cava (IVC) into 3.2% 
sodium citrate (10% v/v, final concentration).  Blood was centrifuged at 150xg for 10 
minutes to separate RBCs from PRP.  RBCs were suspended in sterile 1.29 mM sodium 
citrate  (pH 7.2), 3.33 mM glucose, 124 mM NaCl (CGS) and centrifuged at 250xg for 5 
minutes 3 times to wash RBCs.  Washed RBCs were suspended in sterile 20 mM N-2-
hydroxyethylpiperazine-N’-2-ethane-sulfonic acid (pH 7.4) containing 150 mM NaCl (HBS) 
and centrifuged at 400xg for 10 minutes to “pack” RBCs.  RBCs were counted on a 
! 69 
HV950FS Hemavet cell counter (Drew Scientific, Dallas, TX) and the hematocrit was 
adjusted to 70%.  For RBC transfusions, male, 6- to 8-week old C57Bl/6 mice anesthetized 
and injected with pRBCs via the retro-orbital plexus.  After 24 hours, blood was drawn from 
the IVC or animals were subjected to thrombosis models. 
 
3.2.6 Blood smears.   
Differential staining was performed by fixing smears in methanol, and then incubating in 
Eosin Y and Azure B for one minute each (Diff-stain kit, IMEB, San Marcos, CA).  Stained 
smears were imaged using an Olympus BX61 microscope (Waltham, MA). 
 
3.2.7 Flow cytometry.  
 Whole blood and washed RBCs were diluted 1:500 and 1:1000, respectively, in RBC 
wash buffer (21 mM Tris-base, 140 mM NaCl, 11.1 mM dextrose, 4.7 mM KCl, 1.2 mM 
MgSO4, and 0.1% PEG 8000 at pH 7.4 in the absence and presence of 2.5 mM CaCl2).  
Diluted samples (100 µL) were stained in the dark at room temperature for 30 minutes with 
10 µL FITC-Annexin V for PS detection and 5 µL PE-TER119 for RBC detection.  After 
staining, samples were further diluted with 1000 µL RBC wash buffer and analyzed on a 
Stratedigm S1000Ex flow cytometer (San Jose, CA) using appropriate compensation controls.  
Samples stained in the absence of calcium were used as negative controls.  RBCs treated with 
10 mM N-ethylmaleimide plus 4 µM calcium ionophore A23187 for 30 minutes prior to 
staining were used as positive controls.  PS-positive RBCs were determined by dual positive 
staining for TER119 and Annexin V.  Percent PS-positive RBCs was calculated by dividing 
the number of dual positive events by the total number of TER119 events in each sample. 
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3.2.8 Blood viscosity measurements.  
 Whole blood viscosity was measured using a stress-controlled cone-and-plate rheometer 
(AR-G2, TA Instruments, New Castle, DE), where the cone had a 60 mm diameter and a 1/2º 
cone angle and with the operating temperature set at 37ºC. Startup effects were reduced by 
subjecting samples to a 30 s-1 preshear before beginning the sweep.  The viscosity recorded at 
each shear-rate was the result of the rheometer reaching steady state, where three consecutive 
viscosity measurements integrated over 10 seconds were required to vary from one another 
by less than 5%.  To ensure the history of high shear rates did not affect the overall rheology 
of the blood in repeated measurements, we first ran the shear rate sweep with increasing 
shear rates (from 30 to 2300 s-1) and then repeated the measurement in the opposite direction 
(from 2300 to 30 s-1). 
 
3.2.9 FeCl3 model of arterial thrombosis.   
 FeCl3 injury to carotid arteries was performed as described [25-27].  Briefly, 6- to 8- 
week old male C57Bl/6 mice were anesthetized, and the right common carotid artery was 
exposed, dried, and treated with FeCl3 (10% on 0.5 X 0.5-mm filter paper) for 2 minutes.  
Blood flow was monitored by Doppler ultrasonic flow probe, and the time to vessel 
occlusion was defined as the time between FeCl3 administration and lack of flow for 60 
seconds.  Vessels were excised and fixed in 10% formalin for 24 hours and then transferred 
to 70% ethanol. 
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3.2.10 Measurement of circulating thrombin-antithrombin (TAT) complexes.   
 TAT complexes were measured with plasma prepared from IVC blood draws at baseline 
and after FeCl3/carotid artery thrombosis (in separate mice) by ELISA (Enzygnost TAT 
micro ELISA, Siemens, Munich, Germany).  
 
3.2.11 Histology.   
 Fixed tissues were dehydrated and paraffin-embedded, and consecutive, 5-µm sections 
cut and mounted with vectamount (UNC Lineberger Comprehensive Cancer Center Animal 
Histopathology Core).  Slides were stained with hematoxylin and eosin (H&E), and imaged 
using an Aperio scanner (Leica Biosystems Inc, Buffalo Grove, IL).  Immunohistochemistry 
was performed as described [25].  Briefly, antigen retrieval was performed in a 95°C water 
bath using Target Retrieval Solution (DakoCytomation, Capinteria, CA).  Slides were 
blocked with mouse IgG blocking reagent (Vector Laboratories, Burlingame, CA) and 
stained with anti-fibrin antibody (59D8) for 1 hour in a humidity-controlled chamber.  Slides 
were developed using an avidin-biotin complex (DakoCytomation, Capinteria, CA).  
Simultaneously, negative controls were stained in the absence of primary antibody.  Staining 
intensity of thrombi was performed blindly by six individuals on a scale of 0-3.   
 
3.2.12 Measurement of circulating platelet factor 4 (PF4) levels.  
 PF4 complexes were measured with plasma prepared from IVC blood draws at baseline 
and after FeCl3/ carotid artery thrombosis (in separate mice) by ELISA (Mouse CXCL4/PF4 
Quantikine ELISA, R&D Systems, Minneapolis, MN) 
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3.2.13 Statistical methods.  
 Descriptive statistics (mean, median, standard deviation [SD], and standard error of the 
mean [SEM]) were calculated.  Groups were compared using Student’s t-tests (normally 
distributed data determined by Lilliefors test for normality) or Wilcoxon-Mann–Whitney 
rank sum tests (non-normally distributed data) in Kaleidagraph version 4.1.3 (Synergy 
Software, Reading, PA).  For the viscosity experiments, we logarithmically transformed both 
viscosity and shear rate and used a linear model to describe the relationship between the 
variables.  
 
3.3 Results 
3.3.1 The RBC increase in thrombin generation in whole blood is dependent on platelet 
concentration.  
 Previous studies have shown that RBCs express PS on their cell membrane and that these 
surfaces can support thrombin generation [10-13].  These prior experiments were limited in 
that either only one hematocrit was studied, platelets were absent, or only one platelet 
concentration was tested. Therefore, we separated whole blood from healthy human donors 
into plasma, concentrated PRP, and pRBCs and reconstituted these components to reach 
hematocrits of 0, 20, and 45% in the presence or absence of platelets (200x103/µL or 
450x103/µL platelets, final concentration).  As expected, in the absence of platelets, 
increasing hematocrit strongly increased thrombin generation (P<0.005, Figure 3.1).  When 
platelet concentration was raised to 200x103/µL, increasing hematocrit still increased 
thrombin generation but to a lesser extent (P<0.05) than in the absence of platelets (Figure 
3.1).  Interestingly, when platelet concentration was raised to 450x103/µL, increasing 
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hematocrit did not increase thrombin generation (Figure 3.1).  These data suggest the effect 
of hematocrit on thrombin generation is dependent on platelet concentration.  
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Figure 3.1: The RBC effect on thrombin generation is dependent on platelet 
concentration.  Platelet-poor plasma was reconstituted with 0, 200, or 450 K/µl platelets, 
and 0, 20, or 45% hematocrit, final.  Thrombin generation was measured by calibrated 
automated thrombography. Data are shown as mean±SEM. N=3-6. **P<0.005, *P<0.05. 
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3.3.2 RBC infusion raises hematocrit in mice without altering RBC morphology or PS-
exposure.  
 To determine the effects of elevated hematocrit in vivo, we developed a mouse model in 
which we infused healthy mice with washed pRBCs from healthy donor mice.  Complete 
blood counts showed RBCHIGH mice had elevated hematocrit compared to control mice 
(46.6±0.69 versus 39.32±0.74%, P<0.0001, mean ± SE, Figure 3.2A).  Levels of neutrophils 
and monocytes were the same in controls and RBCHIGH mice (1.05±0.28 versus 1.71±0.35 
K/µL, P=0.15, and 0.28±0.06 versus 0.18±0.04 K/µL, P=0.16 respectively, mean ± SE, 
Figure 3.2B,C).  Platelet levels were slightly lower in RBCHIGH mice compared to controls 
(699.0±33.3 versus 802.2±33.7 K/µL, P=0.04, mean ± SE, Figure 3.2D), likely due to 
expanded blood volume following RBC infusion.  Importantly, platelet counts in both 
controls and RBCHIGH remained within the normal range.  Blood smears demonstrated 
normal RBC morphology in pRBCs before infusion (Figure 3.2E, left), and whole blood 
drawn from control mice (Figure 3.2E, middle), and RBCHIGH mice (Figure 3.2E, right).  
Consistent with previous reports [10, 11, 28, 29], only ~0.5% of pRBCs or circulating RBCs 
in control and RBCHIGH mice expressed PS (Figure 3.2F).  Compared to control mice, blood 
from RBCHIGH mice displayed increased blood viscosity over a range of venous and arterial 
shear rates (30-2300 s-1) (Figure 3.2G).  Together, these data show pRBCs can be infused in 
mice without increasing other cell types, changing RBC morphology, or increasing RBC-PS 
exposure, and establish the murine infusion model as a novel way to increase hematocrit in 
mice. 
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Figure 3.2. RBC transfusion raises hematocrit in recipient mice.  RBCs from “donor” 
mice were transfused into “recipient” mice (RBCHIGH).  Blood was drawn from control and 
RBCHIGH mice after 24 hours.  Complete cell count indicates A) elevated hematocrit, but 
normal B) neutrophil, C) monocyte, and D) platelet numbers.  Blood smears on whole blood 
from control and RBCHIGH mice indicate normal RBC morphology (E) and PS exposure (F).  
G) Viscosity measurements show RBCHIGH mice (closed circles) have increased viscosity at 
low and high sheer compared to control mice (open circles). In A-D each dot is a separate 
mouse, lines indicate median values, and boxes represent the normal range.  Error bars 
represent standard deviation.   
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3.3.3 Compared to controls, RBCHIGH mice have a faster time to arterial occlusion.  
 To determine the effect of elevated hematocrit on thrombus formation, we then subjected 
control and RBCHIGH mice to the FeCl3/carotid artery injury model.  Compared to control 
mice, RBCHIGH mice had a significantly shorter time to occlusion (TTO,12.8±2.2 minutes 
versus 5.3±0.4, respectively [mean ± SEM], P<0.001) Figure 3.3A).  Infusion of RBC wash 
supernatant into mice did not shorten the time to occlusion (Figure 3.3A) indicating the HBS 
wash the RBCs were packed in did not cause thrombosis.  Moreover, 7.7 minutes after FeCl3 
injury, 100% of RBCHIGH mice had an occluded vessel, whereas only 50% and 40% of 
control and HBS-infused mice, respectively, developed vessel occlusion (Figure 3.3B).  
Inspection of the Doppler curves indicated that compared to control mice, RBCHIGH mice 
exhibited an earlier onset (3.0±0.5 versus 1.6±0.4 minutes, respectively, P=0.06) and faster 
rate (0.016±0.002 versus 0.009±0.001 Hz/min, respectively, P<0.009) of thrombus formation 
(Figure 3.3C,D). 
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Figure 3.3.  RBCHIGH mice have a shortened time to vessel occlusion following FeCl3 
injury to the carotid artery.  Control and RBCHIGH mice were subjected to FeCl3 injury to 
the carotid artery.  A) Time to vessel occlusion was recorded via Doppler flow probe.  In 
vessels that did not occlude, TTO was recorded as 20 minutes.  B) Percent of mice occluded 
in 7.7 minutes (the median TTO of control mice).  C) Normalized Doppler curves from 
control (open circles) and RBCHIGH (closed circles) mice indicate the loss of blood flow 
during thrombus formation.  D) Rate of thrombus formation in control and RBCHIGH mice 
was determined by fitting a line to the Doppler curves once blood flow decreased.  
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3.3.4 In vivo thrombin generation does not differ between control and RBCHIGH mice.   
 Figure 3.1 shows that RBCs dose-dependently increase thrombin generation in a static in 
vitro system but not when platelets are present at 450x103/µL.  To determine if RBCs 
increase thrombin generation in vivo, we drew blood from mice following FeCl3-triggered 
thrombus formation and measured plasma TAT complexes.  We found there was no 
difference in plasma TAT levels between RBCHIGH and control mice (7.35±1.09 versus 
5.78±0.65 ng/mL, respectively, P=0.25, mean±SE, Figure 3.4A).  Furthermore, there was 
also no correlation between hematocrit and TATs (Figure 3.4B) and platelet concentration 
and TATs (Figure 3.4C).  These data suggest RBCs do not shorten the TTO by increasing 
thrombin generation. 
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Figure 3.4. Thrombin-antithrombin complexes are similar in control and RBCHIGH mice 
following FeCl3 injury.  A) Plasma TAT complexes were measured by ELISA in control 
and RBCHIGH mice at baseline and after FeCl3 injury. B) Correlation between hematocrit and 
TATs. C) Correlation between platelet concentration and TATs.  
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3.3.5 Thrombi from control and RBCHIGH mice do not differ in size or fibrin content.  
 
 To determine the mechanism of faster TTO in RBCHIGH mice, we excised the occluded 
carotid arteries from mice and stained thrombi with H&E and antibodies against fibrin.  
Thrombi in control and RBCHIGH mice were occlusive and similar in size (Figure 3.5C), and 
H&E staining showed thrombi were primarily composed of protein with small islands of 
RBCs (Figure 3.5A).  Thrombi from control and RBCHIGH mice also did not differ in fibrin 
content (Figure 3.5B).  No fibrin staining was detected in the absence of primary antibody, 
confirming the secondary antibody did not bind to mouse tissue nonspecifically.  These data 
indicate that increasing RBCs produces thrombi of similar size and content, and does not 
increase fibrin deposition in thrombi. 
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Figure 3.5. Thrombi from control and RBCHIGH mice have similar morphology and 
fibrin content. Thrombi were excised, fixed, and analyzed by A) H&E staining and 
immunohistochemistry for B) fibrin (antibody 59D8).  C) Thrombus size was determined by 
measuring pixel area of the thrombus within the vessel.  Scale bar represents 500 µm. 
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3.3.6 PF4 levels did not differ between control and RBCHIGH mice. 
 To determine if platelet activation was increased in RBCHIGH mice, we used PF4 as a 
marker of platelet activation in plasma following FeCl3 arterial injury (Figure 3.6).  However, 
arterial thrombus formation did not increase plasma levels of PF4 despite the formation of 
platelet-rich thrombi in mice (Figure 3.5) suggesting PF4 is a poor marker of platelet 
activation in murine plasma.  Alternatively, since little PF4 was measured in plasmas 
following platelet-rich thrombus formation, it could be possible that platelets are aggregating, 
without degranulating, and thus platelet PF4 is maintained in the α-granuoles without being 
released into the plasma.  
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Figure 3.6. PF4 levels did not differ between control and RBCHIGH mice.  PF4 was 
measured by ELISA in plasma from control and RBCHIGH mice at baseline and following 
FeCl3 injury and clot formation.  Uninjured murine whole blood spun to plasma served as a 
negative control.  Murine whole blood activated with thrombin, then centrifuged to PPP 
served as a positive control.     
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3.4 Discussion 
 
 Although epidemiological studies have associated RBC transfusion and high hematocrit 
with arterial thrombosis, the causal role of RBCs in thrombosis has been controversial.  
Additionally, the mechanism by which RBCs promote thrombus formation is unclear.  
Herein, we measured thrombin generation in vitro in reconstituted blood with increasing 
RBCs and platelets.  We found that RBCs increased thrombin generation in the absence of 
platelets, although effects were blunted and eventually absent as platelet count increased.  To 
determine if RBCs cause arterial thrombosis in vivo, we infused RBCs into mice and showed 
that RBCHIGH mice have a faster TTO than controls.  TAT measurements from plasma 
following arterial injury showed no difference between RBCHIGH and controls.  These data 
suggest thrombosis was not accelerated by RBC-driven thrombin generation. 
 Similar to previous studies, we found that RBCs increased thrombin generation in vitro, 
but extended these findings by showing that the RBC influence on thrombin generation was 
dependent on the concentration of another PS-positive surface (platelets).  In our in vivo 
model, control and RBCHIGH mice had an average platelet count of 802.2±33.7 and 
699.0±33.3 K/µL, respectively.  This high platelet count may be a reason why RBC-
supported thrombin generation did not drive thrombosis in vivo.  However, RBC-supported 
thrombin generation may play a greater role in vivo role under thrombocytopenic conditions. 
Since in our in vivo model, RBCs accelerated thrombosis independent of thrombin generation, 
and our model was performed in an arterial bed in which thrombi are platelet-rich, it is likely 
that RBCs cause thrombosis via their influence on platelets.  Experiments to test this 
hypothesis and preliminary data are described in Chapter 4.    
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 Since our study shows elevated hematocrit did not accelerate thrombosis via increasing 
thrombin generation, we suggest that use of anticoagulants would be ineffective in 
preventing thrombosis in patients with an elevated hematocrit.  In fact, a retrospective 
analysis of patients with PV receiving secondary prophylaxis with oral anticoagulants 
showed 20% of patients displayed recurrent arterial thrombosis, and 20% of patients 
developed bleeding [30].  Even though this study was performed in patients with a backdrop 
of PV, RBCs from patients with PV have been shown to have increased PS-exposure [14] 
which would suggest RBC-supported thrombin generation may play a greater role in 
thrombosis in this population compared to a population with elevated RBCs with normal PS 
exposure.  These data further support the idea that RBCs cause thrombosis independent of 
thrombin generation and that anticoagulation may even cause more harm then good in 
patients with an elevated hematocrit. 
 Since RBCs did not accelerate thrombosis via increasing thrombin generation, we 
hypothesized that RBCs promoted thrombosis via a platelet-mediated mechanism.     
Antiplatelet therapy has been shown to be successful in preventing thrombosis in patients 
with elevated hematocrit caused by PV.  The efficacy of low-dose aspirin was tested by the 
European Collaboration on Low-Dose Aspirin in Polycythemia Vera Project (ECLAP) in a 
double-blind, placebo controlled, randomized clinical trial [31].  Aspirin significantly 
lowered the risk of cardiovascular death, non-fatal MI, and non-fatal stroke compared to 
placebo control without causing significant bleeding.  These data show platelet inhibition 
helps prevent thrombosis with patients with PV and suggest elevated RBCs may cause 
arterial thrombosis via a platelet-mediated mechanism. 
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 Previous studies have used animal models to study the effects of elevated hematocrit on 
bleeding, thrombosis, and blood flow.  These models induced RBC production through 
overproduction of erythropoietin or by JAK 2V617F-induced PV.  In erythropoietin-induced 
erythrocytosis, studies have found a range of phenotypes.  Zebrafish with increased 
expression of erythropoietin (via mRNA injection) show increased blood viscosity, reduced 
blood flow, localized vascular stasis, and had a high mortality rate, however thrombosis 
models were not utilized in this study [32].  Interestingly, mice overexpressing human 
erythropoietin that reached a hematocrit of 80-85% demonstrated a bleeding phenotype [33].  
The authors conclude bleeding is due to reduced coagulation activity due to a lack of plasma 
volume.  However, this hematocrit is not physiologic, making it difficult to translate these 
results to high hematocrits seen in patients.  Hematocrit has also been raised in mice via 
treatment with human recombinant erythropoietin but no difference in thrombosis was found 
compared to controls [34].  However, erythropoietin has been implicated in a wide range of 
activities on different cell types and organ systems including immune cells, endothelial cells, 
bone marrow stromal cells, and cells of the heart, reproductive system, gastrointestinal tract, 
muscle, kidney, pancreas, and nervous system [35-40].  Thus, it is hard to draw conclusions 
about RBCs and thrombosis in models using erythropoietin.   
 Lamrani et al studied thrombosis in mice that developed JAK 2V617F-induced PV [34].   
Interestingly, mice with PV had increased bleeding in a tail bleed model but had a 
prothrombotic phenotype following FeCl3 injury to mesenteric vessels.  However, PV mice 
also had a platelet GPVI deficiency, and a reduced number of plasma von Willebrand factor 
multimers [34].  Therefore, studying the effect of high hematocrit in the backdrop of PV 
makes defining the role of RBC in thrombosis difficult to interpret. 
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 Our novel model of elevated hematocrit using RBC infusion represents a means of 
studying the effects of RBCs in mice.  Although mice had a slight decrease in platelet count 
this model allowed for elevation of just RBCs without substantially affecting other cell types.  
This model also showed consistent elevation of RBCs to levels that resembled pathologically 
high levels in humans.  Finally, this model lends itself to further manipulation of RBCs ex 
vivo (i.e. storage or gluteraldehyde treatment to increase stiffness) or use of RBCs from mice 
strains with RBC abnormalities such as SCD or PV so different RBC properties can be 
studied.    
 FeCl3 is a commonly used method to induce thrombosis in animal models.  A previous 
study suggested RBCs play a role in thrombosis following FeCl3-induced vascular injury by 
being the first cells to adhere to FeCl3-treated endothelial surfaces [41].  This RBC adhesion 
could serve as a limitation of interpreting our data since in this model increasing hematocrit 
may increase the number of RBCs binding to the endothelium following FeCl3 injury.  
Therefore, future experiments will test the role of RBCs in other models of hemostasis and 
thrombosis.  
 In summary, our results show that RBCs increased thrombin generation in vitro in the 
absence of platelets, but platelet concentration mediates the RBC effect on thrombin 
generation.  Moreover, we developed a novel model of elevated hematocrit in mice and 
found elevated hematocrit is causative in arterial thrombus formation in vivo.  However, 
thrombosis was not due to increased thrombin generation or fibrin formation.  Future studies 
(discussed in Chapter 4) are warranted to determine the mechanism by which elevated 
hematocrit causes thrombosis including RBC influences on blood rheology and biochemical 
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effects on platelet activation and aggregation.  Knowledge of the mechanism by which RBCs 
cause thrombosis will help guide in therapeutic strategies in patients with elevated hematocrit.  
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Chapter 4: Summary and Future Directions 
 
4.1 Summary 
  
Arterial thrombosis is a leading cause of death and disability worldwide, but the 
specific mechanisms leading to thrombus formation are not well-defined.  Numerous 
epidemiological studies have made associations between blood hypercoaguability and risk of 
arterial thrombosis.  These associations have primarily been studied in in vitro systems where 
purified components of blood are studied in isolation or in the presence of a limited number 
of additional blood components.  Therefore, this dissertation utilized plasma-based in vitro 
systems and novel in vivo murine models to study how a form of plasma hypercoaguability 
(elevated γ’-fibrinogen) and cellular hypercoagabulity (elevated RBCs) influence arterial 
thrombus formation.  The goal of this research was to determine if elevated levels of γ’-
fibrinogen and/or RBCs are directly causative in arterial thrombosis or just biomarkers of a 
different pathology. 
 
4.2 Future Directions 
 
We have shown using a murine model that γA/γA, not γA/γ’, is the fibrinogen 
isoform responsible for causing arterial thrombosis [1].  This was an interesting finding since 
epidemiological studies have associated elevated γA/γ’ fibrinogen with arterial thrombosis 
[2-7]. To date, studies measuring γA/γ’ fibrinogen levels in patient plasma have sampled 
blood following arterial thrombosis.  We hypothesize that the elevated γA/γ’ fibrinogen 
levels measured in these plasmas is due to an inflammatory response following thrombus 
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formation.  Data to support this hypothesis came from a study on the effects of the 
proinflammatory cytokines (e.g. IL-6) on fibrinogen expression by HEPG2 cells [8].  Using 
an in vitro system of cultured cells, the authors found that IL-6 upregulates γ’ production to a 
greater extent than γA production [8].  Therefore we propose γ’ may be increased in response 
to the thrombus and not causative in the development of the thrombus as was previously 
thought.  Prospective studies are needed to determine if γA/γ’ levels are actually elevated 
prior to thrombus formation.  This will give further insight into the role of γA/γ fibrinogen in 
arterial thrombosis in humans.  Even though our model showed γA/γ’ is not causative in 
arterial thrombosis, it may serve as a good biomarker of an ongoing inflammatory process. 
There are several mechanisms by which RBCs can promote thrombosis including 
increasing platelet margination toward the vessel wall, increasing platelet aggregation and 
activation, and increasing plasma thrombin generation.  These mechanisms present several 
different therapeutic strategies to prevent thrombus formation including phlebotomy, platelet 
antagonism, and anticoagulation (Figure 4.1).  However, our data suggest RBCs do not 
increase thrombus fibrin content or thrombin generation in a mouse model of arterial 
thrombosis suggesting anticoagulation would not be an appropriate therapeutic strategy in 
patients with high hematocrit.  
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Figure 4.1.!Conceptual model showing influence of RBCs on thrombus formation and 
therapeutic targets. RBCs increase viscosity, promote platelet interactions with the vessel 
wall, and increase thrombin generation. Phlebotomy, platelet antagonism, and anticoagulants 
are candidates for reducing thrombotic risk with elevated hematocrit.  Our data suggest 
anticoagulants would not be a good therapeutic strategy since elevated hematocrit promotes 
thrombosis independent of thrombin generation and fibrin formation.!
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Future experiments on RBCs should focus on determining the mechanism by which 
RBCs promote thrombosis in vivo.  To test the hypothesis that RBCs accelerate thrombosis 
via a platelet dependent mechanism, we will use ex vivo microfluidic chambers to test the 
effect of elevated hematocrit on the rate and total amount of platelet and fibrin accumulation 
on collagen.  We have an active collaboration with Drs. Keith Neeves and Adam Wufsus at 
Colorado School of Mines; they are currently performing these experiments and have 
preliminarily found increasing hematocrit dose-dependently increases platelet accumulation 
on collagen (Figure 4.2A).  However, increasing hematocrit did not increase fibrin(ogen) 
accumulation between 45% and 60% hematocrit with only a slight increase from 30%-45%.  
(Figure 4.2B).   These data are consistent with our murine model described in Chapter 3 in 
that RBCs do not increase fibrin deposition in clots.  Furthermore, this data suggest RBCs 
contribute to thrombosis via a platelet-mediated mechanism. 
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Figure 4.2. Platelet and fibrin(ogen) fluorescent intensity. A) Integrated fluorescent 
intensity of Pacific-Blue anti-CD41 labeled platelets and B) Alexa Fluor-488 labeled 
fibrinogen as a function of time for the 30 (blue), 45 (red), and 60 (black) hematocrit blood 
clots. Lines are the mean and the shaded region is the standard deviation of 6-10 collagen 
spots from three separate assays.  Experiments performed in collaboration with, and printed 
with permission from Drs. Keith Neeves and Adam Wufsus at the Colorado School of Mines.   
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Next, we plan to add a platelet antagonist to the reconstituted blood used in the 
microfluidic model to determine if RBCs promote thrombosis via a platelet mediated 
mechanism.  Moreover, we will utilize a murine model where RBCHIGH  and control mice are 
treated with a platelet antagonist and subjected to FeCl3 injury to the carotid artery.  We 
expect inhibiting platelets will eliminate the effect of elevated hematocrit on thrombosis by 
reducing RBC-induced platelet activation and aggregation.  In sum, these experiments will 
determine if RBCs promote thrombosis via increasing platelet activation and aggregation in 
response to a procoagulant stimulus.   
 Our novel mouse model of elevated hematocrit may be useful for studying other 
RBC-related pathologies.  For example, in transfusion medicine it is controversial whether 
RBC storage increases the procoagulant nature of RBCs [9, 10].  Similarly, sickled RBCs 
have been shown to have abnormal PS expression, stiffness, and adhesive properties but it is 
unclear if these properties contribute to thrombus formation [11].  It would be interesting to 
combine the RBC infusion model using RBCs that have been stored, treated with 
gluteraldehyde, or that have been isolated from mice with sickle cell disease to determine if 
RBCs are specifically responsible for thrombosis in these pathologies.  Additionally, it would 
be interesting to perform an RBC transfusion and subject mice to models of venous 
thrombosis to determine how RBCs influence clot formation under different vascular 
conditions.  Knowledge of the influence of both normal and abnormal RBCs to arterial and 
venous thrombosis may help provide insight in the mechanisms by which RBCs cause 
thrombosis, and thus prevent thrombosis in patients with elevated hematocrit, and patients 
with RBC abnormalities.  Additionally, knowledge of the mechanism by which RBCs cause 
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thrombosis may also guide therapeutic strategies in patients with elevated hematocrit and 
RBC disorders. 
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